[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36471
1. Iuchi Y, Sato K, Jimbo J, Inamura J, Shindo M, Ikuta K, Shinzaki H, Ohnishi K, Watanabe S, Torimoto Y, Kohgo Y: [Acute lymphoblastic leukemia with t(4;11)(q21;q23) after iodine-131 treatment for thyroid cancer]. Rinsho Ketsueki; 2005 Nov;46(11):1202-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia with t(4;11)(q21;q23) after iodine-131 treatment for thyroid cancer].
  • She was given the diagnosis of pro-B acute lymphoblastic leukemia (pro-B ALL).
  • She had never been exposed to any kind of chemoradiotherapy other than 131I therapy and her leukemia showed a t(4;.
  • Although leukemia has been recognized as a late uncommon complication after 131I therapy for thyroid cancer, to the best of our knowledge this is the first patient who developed ALL with t(4 ;11) after 131I therapy among patients with thyroid cancer.
  • [MeSH-major] Chromosome Aberrations. Iodine Radioisotopes / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Thyroid Neoplasms / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440804.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


2. Cardone S, Yen MT, Chévez-Barrios P, Foroozan R, Yen KG: Recurrent acute lymphoblastic leukemia presenting in the lacrimal gland. Ophthal Plast Reconstr Surg; 2006 Jan-Feb;22(1):56-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent acute lymphoblastic leukemia presenting in the lacrimal gland.
  • A 14-year-old girl with a history of acute lymphoblastic leukemia presented with periorbital swelling of the right eyelid associated with enlargement of the lacrimal gland and cervical lymphadenopathy.
  • The patient underwent an incisional biopsy of the lacrimal gland that showed atypical lymphocytes consistent with recurrent acute lymphoblastic leukemia.
  • The lacrimal gland is a rare extramedullary site for recurrence of this disease.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418669.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Winick N: Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed? Pediatr Blood Cancer; 2009 Dec;53(6):922-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed?
  • [MeSH-major] Immunization. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


Advertisement
4. Pietrzyk JJ, Bik-Multanowski M, Balwierz W, Skoczen S, Wojcik D, Chybicka A, Sikorska-Fic B, Matysiak M, Szczepanski T, Sonta-Jakimczyk D, Ploszynska A, Balcerska A, Mycko K, Bodalski J, Krawczuk-Rybak M, Kowalczyk J, Koltan A, Sobol G, Derwich K, Kwinta P: Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene. Pediatr Blood Cancer; 2009 Mar;52(3):364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene.
  • The objective of this prospective multicenter study was to evaluate the role of selected polymorphisms of genes associated with metabolism of chemotherapeutic drugs as prognostic markers in children with acute lymphoblastic leukemia.
  • [MeSH-major] 5,10-Methylenetetrahydrofolate Reductase (FADH2) / genetics. Genetic Predisposition to Disease / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2009 Mar;52(3):316-7 [19058213.001]
  • (PMID = 18989887.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / 5,10-Methylenetetrahydrofolate Reductase (FADH2)
  •  go-up   go-down


5. Hoshino T, Tahara K, Miyawaki K, Hatsumi N, Takada S, Miyawaki S, Sakura T: [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib]. Rinsho Ketsueki; 2010 Mar;51(3):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
  • We retrospectively analyzed the clinical outcome of dasatinib in 7 patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to imatinib.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Thiazoles / administration & dosage


6. Drake-Lee A: Left-right discrimination. It's all about coordination and laterality. BMJ; 2009;338:b34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left-right discrimination. It's all about coordination and laterality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] BMJ. 2008;337:a2906 [19088147.001]
  • (PMID = 19136539.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


7. Salisbury DM: (Not) warts and all. Government fully considered HPV vaccine. BMJ; 2008;337:a2552
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (Not) warts and all. Government fully considered HPV vaccine.
  • [MeSH-major] Condylomata Acuminata / prevention & control. Papillomavirus Vaccines
  • [MeSH-minor] Cost-Benefit Analysis. Government Programs. Great Britain. Humans

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] BMJ. 2008;337:a2186 [18948345.001]
  • (PMID = 19019858.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


8. Lim KH, Kim S, Lee YS, Kim KH, Kim J, Rhee Jy, Kim HJ, Yi HG, Oh SY, Lim JH, Han SW, Lee S, Kim I, Yoon SS, Park S, Kim BK: Central pontine myelinolysis in a patient with acute lymphoblastic leukemia after hematopoietic stem cell transplantation: a case report. J Korean Med Sci; 2008 Apr;23(2):324-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pontine myelinolysis in a patient with acute lymphoblastic leukemia after hematopoietic stem cell transplantation: a case report.
  • We describe a 37-yr-old man who developed central pontine myelinolysis (CPM) after allogeneic hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia.
  • The liver biopsy of the patient indicated graft-versus-host disease- related liver disease, and the dose of methylprednisolone was increased.
  • We report a rare case in which hepatic dysfunction due to graft-versus-host disease has a strong association with CPM after HSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Myelinolysis, Central Pontine / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Biopsy. Brain / pathology. Electroencephalography. Graft vs Host Disease. Humans. Hyperbilirubinemia / etiology. Liver / pathology. Magnetic Resonance Imaging. Male. Time Factors. Treatment Outcome


9. Hill G, Chauvenet AR, Lovato J, McLean TW: Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics; 2005 Oct;116(4):e525-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.
  • Children with acute lymphoblastic leukemia (ALL) are treated with intermittent steroid therapy.
  • Cases of varicella were coded 1 to 5 on the basis of severity: grade 1 caused minimal to no symptoms, grade 2 caused mild to moderate symptoms that did not require hospitalization, grade 3 caused symptoms severe enough to require hospitalization and intravenous acyclovir, grade 4 caused severe disease that had complications or that required intensive care, and grade 5 resulted in death.
  • For analysis, disease grade was dichotomized into nonsevere (grades 1 and 2) and severe (grades 3, 4, and 5).
  • Of the 110 patients, 56 had nonsevere disease; 54 had severe disease, including 2 deaths.
  • By multivariate analysis, older age at ALL diagnosis, years from ALL diagnosis to VZV diagnosis, and VZV diagnosis within the 4-week period of interest (during or within 3 weeks of prednisone therapy) all were independently associated with an increased risk for severe infection.
  • [MeSH-major] Chickenpox / complications. Glucocorticoids / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / adverse effects


10. Barry EV, Silverman LB: Acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep; 2008 Jul;3(3):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents and young adults.
  • Age at diagnosis remains one of the strongest prognostic factors in acute lymphoblastic leukemia (ALL), with older patients having inferior outcomes compared with younger patients.
  • Compared with younger children with ALL, AYAs are more likely to present with unfavorable presenting characteristics (such as high presenting leukocyte counts, T-cell phenotype, and the Philadelphia chromosome).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Agents / toxicity. Fusion Proteins, bcr-abl / genetics. Humans. Immunophenotyping. Leukocyte Count. Prospective Studies. Stem Cell Transplantation. Survival Rate. Translocation, Genetic. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):166-73 [16029445.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1551-61 [16955505.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):813-9 [17327603.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3262-72 [10986059.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 2008 Feb;22(2):308-12 [17989709.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1843-9 [18398150.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):310-20 [16307416.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1253-8 [11830473.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1677-84 [15378506.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):220-5 [15514916.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):254-61 [16421910.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):635-42 [16112299.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):803-10 [15953008.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • (PMID = 20425461.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


11. Chatterjee R, Singh O, Pachuau L, Malik SP, Paul M, Bhadra K, Paul S, Kumar GS, Mondal NB, Banerjee S: Identification of a sulfonoquinovosyldiacylglyceride from Azadirachta indica and studies on its cytotoxic activity and DNA binding properties. Bioorg Med Chem Lett; 2010 Nov 15;20(22):6699-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SQDG induces apoptosis in a dose dependent manner with IC(50) 8.3 μM against acute lymphoblastic leukemia (ALL) MOLT-4 cell lines.
  • [MeSH-minor] Animals. Calorimetry. Cattle. Cell Line, Tumor. Humans. Inhibitory Concentration 50. Magnetic Resonance Spectroscopy. Mass Spectrometry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [ErratumIn] Bioorg Med Chem Lett. 2011 Mar 15;21(6):1901
  • (PMID = 20932749.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diglycerides; 9007-49-2 / DNA
  •  go-up   go-down


12. Zhang X, Wang M, Zhou C, Chen S, Wang J: The expression of iASPP in acute leukemias. Leuk Res; 2005 Feb;29(2):179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of iASPP in acute leukemias.
  • To examine the role of iASPP in acute leukemia (AL), we analyzed iASPP mRNA expression in AL by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
  • There was no significant difference between acute lymphocytic leukemia (ALL) cells and acute myeloid leukemia (AML) cells (P = 0.593).
  • However, iASPP gene expression in AL cells was not associated with gender, age, initial white blood cell count or p53 type, but was associated with CD34 expression.
  • The results of the present study suggest that iASPP gene overexpression may play an important role in the leukemogenesis and/or disease progression of AL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Intracellular Signaling Peptides and Proteins / genetics. Leukemia, Myeloid, Acute / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Female. Humans. Male. Mutation. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Suppressor Protein p53 / antagonists & inhibitors. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607367.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / PPP1R13L protein, human; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


13. He YL, Li CF, Shi L: [High dose methotrexate induced acute renal insufficiency in a patient with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 Jan;45(1):78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose methotrexate induced acute renal insufficiency in a patient with acute lymphoblastic leukemia].
  • [MeSH-major] Acute Kidney Injury / chemically induced. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349162.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Clappier E, Cuccuini W, Cayuela JM, Vecchione D, Baruchel A, Dombret H, Sigaux F, Soulier J: Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia; 2006 Jan;20(1):82-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias.
  • While the cyclin D1 and D3 genes (CCND1 and CCND3) are recurrently involved in genomic rearrangements, especially in B-cell lymphoid neoplasias, no clear involvement of the cyclin D2 gene (CCND2) has been reported to date.
  • Here, we identified chromosomal translocations targeting the CCND2 locus at 12p13, and the T-cell receptor beta (TCRB) or the TCRA/D loci in T-cell acute lymphoblastic leukemias (T-ALLs).
  • Expression analysis demonstrated dramatic cyclin D2 overexpression in the translocated cases (n=3) compared to other T-ALLs (total, n=89).
  • In order to evaluate dysregulation in T-ALL with respect to normal T-cell differentiation, we analyzed CCND2 expression in normal purified human thymic subpopulations.
  • CCND2 levels were downregulated through progression from the early stages of human T-cell differentiation, further suggesting that the massive and sustained expression in the CCND2-rearranged T-ALL cases was oncogenic.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. Cyclins / biosynthesis. Cyclins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Receptors, Antigen, T-Cell / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Cell Separation. Child. Cyclin D2. Cytogenetic Analysis. DNA Mutational Analysis. Gene Rearrangement. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270038.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


15. Hammond SM, Crable SC, Anderson KP: Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk Res; 2005 Jan;29(1):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.
  • Ectopic expression of LMO2 occurs in approximately 45% of T-lineage acute lymphoblastic leukemias (T-ALL), sometimes in association with chromosomal translocations.
  • Recently, a lymphoproliferative disorder developed in two participants in a gene therapy trial due to LMO2 activation via integration of the retroviral vector.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia / genetics. Metalloproteins / genetics. Proto-Oncogenes. Regulatory Sequences, Nucleic Acid. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15541480.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / Hydroxamic Acids; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins; 3X2S926L3Z / trichostatin A; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


16. Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J, Sigaux F, Chan S, Kastner P, Ghysdael J: Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia; 2010 Jun;24(6):1200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
  • [MeSH-major] Fusion Proteins, bcr-abl / physiology. Genes, Tumor Suppressor / physiology. Ikaros Transcription Factor / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


17. Mandal C, Srinivasan GV, Chowdhury S, Chandra S, Mandal C, Schauer R, Mandal C: High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status. Glycoconj J; 2009 Jan;26(1):57-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status.
  • Previous studies had established an over-expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • Here, we report the discovery and characterization of sialate-O-acetyltransferase enzyme in ALL-cell lines and lymphoblasts from bone marrow of children diagnosed with B- and T-ALL.
  • Sialate-O-acetyltransferase activity in cell lysates or microsomal fractions of lymphoblasts of patients was always higher than that in healthy donors reaching up to 22-fold in microsomes.
  • Sialate-O-acetyltransferase activity increased at the diagnosis of leukaemia, decreased with clinical remission and sharply increased again in relapsed patients as determined by radiometric-assay.
  • [MeSH-major] Acetyltransferases / metabolism. Bone Marrow / enzymology. Microsomes / enzymology. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Acetyl Coenzyme A / metabolism. Adolescent. Cell Line, Tumor. Child. Child, Preschool. Cytidine Monophosphate / metabolism. Humans. Infant. Male. N-Acetylneuraminic Acid / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Feb;13(2):309-12 [10025909.001]
  • [Cites] Biol Chem. 2004 Feb;385(2):145-52 [15101557.001]
  • [Cites] Biochim Biophys Acta. 1961 Sep 16;52:349-60 [14477442.001]
  • [Cites] Eur J Biochem. 2004 Jan;271(2):281-90 [14717696.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):177-91 [15629900.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1403-10 [2302705.001]
  • [Cites] Zoology (Jena). 2004;107(1):49-64 [16351927.001]
  • [Cites] Glycoconj J. 2006 Dec;23(9):627-38 [17115281.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15130-8 [8662976.001]
  • [Cites] Glycoconj J. 2000 Jul-Sep;17(7-9):485-99 [11421344.001]
  • [Cites] Glycoconj J. 2007 Jan;24(1):17-24 [17146715.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Glycoconj J. 1998 Sep;15(9):895-904 [10052593.001]
  • [Cites] J Biol Chem. 1988 Feb 5;263(4):2079-86 [3339003.001]
  • [Cites] Biochem Z. 1958;329(6):490-507 [13535603.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):254-60 [11180001.001]
  • [Cites] Hoppe Seylers Z Physiol Chem. 1982 Mar;363(3):255-62 [7076126.001]
  • [Cites] J Biol Chem. 1981 Jan 25;256(2):989-93 [7451485.001]
  • [Cites] Carbohydr Res. 1995 Mar 1;268(1):115-25 [7736461.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):35-41 [15606547.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):801-12 [11054061.001]
  • [Cites] Glycobiology. 2004 Oct;14(10):859-70 [15190007.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):270-7 [15197782.001]
  • [Cites] Biol Chem. 2007 Mar;388(3):297-306 [17338637.001]
  • [Cites] Glycoconj J. 1999 Jun;16(6):307-17 [10579699.001]
  • [Cites] Methods Enzymol. 1994;230:168-99 [8139495.001]
  • [Cites] J Biochem. 1998 Jul;124(1):111-21 [9644253.001]
  • [Cites] J Biol Chem. 1979 Feb 10;254(3):789-95 [83994.001]
  • [Cites] Chem Rev. 2002 Feb;102(2):439-69 [11841250.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1535-41 [12486096.001]
  • [Cites] Leukemia. 1999 Jan;13(1):119-25 [10049046.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5165-71 [8912852.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10197-206 [8486687.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):162-6 [2757191.001]
  • [Cites] J Biol Chem. 1985 Jun 10;260(11):6600-8 [3997840.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):7825-33 [16434401.001]
  • [Cites] Biochimie. 1998 Jan;80(1):49-57 [9587662.001]
  • [Cites] Eur J Biochem. 1981 Jun;117(1):41-55 [7262089.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 26;362(3):651-7 [17761143.001]
  • (PMID = 18677580.001).
  • [ISSN] 1573-4986
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 72-89-9 / Acetyl Coenzyme A; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / N-acylneuraminate-9(7)-O-acetyltransferase; F469818O25 / Cytidine Monophosphate; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


18. de Andrade CF, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA: CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem; 2009 Jun;24(3):708-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.
  • In this study, we analyzed the CD26 antigen cell membrane expression by flow cytometry and the DPPIV activity in plasma of patients of acute leukemia.
  • The results showed that the plasma DPPIV activity is significantly higher in leukemia patients and could be 100% inhibited by Januvia (Merck Sharp & Dohme) a selective DPPIV inhibitor.
  • Although CD26 expression on immune cells were not leukemia-dependent the analysis of the correlation between CD26 expression and the DPPIV plasma activity were statistically significant (p < 0.01) in acute lymphoid leukemia (B-ALL and T-ALL).
  • [MeSH-major] Cell Membrane / metabolism. Dipeptidyl Peptidase 4 / blood. Dipeptidyl Peptidase 4 / metabolism. Gene Expression Regulation, Neoplastic. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. SITAGLIPTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469710.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dipeptidyl-Peptidase IV Inhibitors; 0 / Pyrazines; 0 / Triazoles; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4; TS63EW8X6F / Sitagliptin Phosphate
  •  go-up   go-down


19. Russell EB: Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol; 2005 Sep;32(9):1760-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate whether the remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome may represent a paraneoplastic disorder in a significant percentage of cases.
  • METHODS: Patients diagnosed with RS3PE syndrome at the Medical College of Wisconsin before 1995 were telephoned and asked about their rheumatologic course since initial diagnosis of RS3PE and whether they had been diagnosed with any cancer.
  • Criteria used for diagnosis of RS3PE syndrome included sudden onset of painful diffuse swelling of both hands associated with pitting edema of the dorsa of the hands without other synovitis or evidence of disease, negative rheumatoid factor, absence of radiologic abnormalities, and resolution within 6-12 months without sequelae.
  • Four had a cancer diagnosed following recognition of the RS3PE syndrome; 1 patient developed non-Hodgkin's lymphoma initially diagnosed as hairy cell leukemia after 4 years; 1 developed acute lymphocytic leukemia with hyperdiploidy after 14 years; 1 was diagnosed with male breast cancer after 2.5 years; and 1 developed squamous cell lung cancer 12 months after RS3PE diagnosis.
  • The interval between onset of RS3PE syndrome and diagnosis of cancer was fairly long, indicating that patients should be monitored for neoplasia with prudent age and sex specific surveillance for an extended period after diagnosis with RS3PE.
  • [MeSH-major] Edema / diagnosis. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / epidemiology. Precancerous Conditions / pathology. Synovitis / diagnosis

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Synovitis.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Rheumatol. 2006 Nov;33(11):2365-6; author reply 2366 [17086622.001]
  • [CommentIn] J Rheumatol. 2007 Feb;34(2):452-3 [17304672.001]
  • (PMID = 16142875.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


20. Bierings M, Nachman JB, Zwaan CM: Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges. Curr Stem Cell Res Ther; 2007 Jan;2(1):53-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges.
  • The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in children has changed over the past decade.
  • In pediatric acute lymphoblastic leukemia (ALL), the overall cure-rate is high with conventional chemotherapy.
  • However, selected patients with a high-risk of relapse are often treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first remission (CR1).
  • High minimal residual disease (MRD) levels directly prior to HSCT determines the relapse risk.
  • In pediatric acute myeloid leukemia (AML) the role of allo-HSCT in CR1 is declining, due to better outcome with modern multi-agent chemotherapy.
  • Targeted therapy may change the role of HSCT, in particular in chronic myeloid leukemia, where the role of allografting is changing in the imatinib era.
  • New developments in HSCT, such as the role of alternative conditioning regimens, and innovative stem cell sources such as peripheral blood and cord blood, will also be addressed.
  • [MeSH-major] Leukemia / therapy. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation / trends
  • [MeSH-minor] Child. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy


21. Pinkerton R, Wills RA, Coory MD, Fraser CJ: Survival from haematological malignancy in childhood, adolescence and young adulthood in Australia: is the age-related gap narrowing? Med J Aust; 2010 Aug 16;193(4):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING AND PARTICIPANTS: Population-based study of all Australian children (aged 0-14 years), adolescents (15-19 years) and young adults (20-29 years) diagnosed with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between 1982 and 2004, with follow-up to 2006.
  • MAIN OUTCOME MEASURES: 5-year survival from ALL, AML, HL and NHL analysed for four periods of diagnosis (1982-1989, 1990-1994, 1995-1999 and 2000-2004).
  • RESULTS: During 1982-2004, 13 015 people aged < or = 29 years were diagnosed with primary leukaemia or lymphoma in Australia.
  • For lymphoma cases diagnosed in 2000-2004, 5-year survival in all age groups was greater than 95% for HL and greater than 81% for NHL, although children fared better than adolescents and young adults.
  • [MeSH-major] Leukemia / mortality. Lymphoma / mortality

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712542.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


22. Mrózek K, Harper DP, Aplan PD: Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Oct;23(5):991-1010, v
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics and molecular genetics of acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a malignant disease that often features nonrandom numerical or structural chromosome aberrations that can be detected microscopically.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1996 Sep;10(9):1456-8 [8751462.001]
  • [Cites] Br J Haematol. 1996 Dec;95(4):678-91 [8982045.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):601-10 [9054669.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):93-100 [9359508.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):527-35 [9469337.001]
  • [Cites] Leukemia. 1998 May;12(5):779-87 [9593281.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1537-44 [10477677.001]
  • [Cites] Clin Genet. 2004 Dec;66(6):488-95 [15521975.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Leukemia. 2005 May;19(5):734-40 [15789069.001]
  • [Cites] Leukemia. 2005 Apr;19(4):557-63 [15744345.001]
  • [Cites] Leukemia. 2005 Apr;19(4):564-71 [15716990.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1179-85 [16154840.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Leukemia. 2006 Mar;20(3):410-6 [16424874.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):891-7 [16525638.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4508-13 [16493009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8167-72 [16702559.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4376-84 [18802149.001]
  • [Cites] Br J Haematol. 2008 Sep;142(6):934-45 [18557744.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):3-15 [19100363.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):24-32 [19100365.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Leukemia. 2009 Jan;23(1):125-33 [18923437.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):125-34 [19138562.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1756-8 [19109563.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2375-85 [19056693.001]
  • [Cites] Cancer. 2009 May 15;115(10):2147-54 [19298009.001]
  • [Cites] Blood. 2009 May 7;113(19):4489-96 [19244158.001]
  • [Cites] Br J Haematol. 2009 Jun;146(1):113-5 [19344409.001]
  • [Cites] Blood. 2009 Jul 30;114(5):937-51 [19357394.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1406-9 [19282835.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4036-45 [10590047.001]
  • [Cites] Cancer Invest. 2000;18(2):135-47 [10705876.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1945-54 [10760773.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):467-78 [10784391.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1876-87 [10784628.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):147-53 [10930992.001]
  • [Cites] Eur J Haematol. 2000 Mar;64(3):194-200 [10997886.001]
  • [Cites] Leukemia. 2001 Mar;15(3):468-72 [11237073.001]
  • [Cites] Eur J Haematol. 2001 May;66(5):297-304 [11422408.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Eur J Haematol. 2002 Jan;68(1):31-41 [11952819.001]
  • [Cites] Leukemia. 2002 Apr;16(4):669-74 [11960348.001]
  • [Cites] Leukemia. 2002 May;16(5):776-84 [11986937.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jun;34(2):137-53 [11979548.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Leukemia. 2003 Mar;17(3):547-53 [12646943.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1085-9 [16533526.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2327-30 [17095619.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):684-93 [17431878.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Leuk Res. 2008 Jan;32(1):39-43 [17418891.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Haematologica. 2008 Feb;93(2):287-90 [18223280.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):572-7 [18275435.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2563-72 [18156492.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):665-72 [18241254.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2186-91 [18445843.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1117-24 [18401417.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):239-44 [18636143.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Jul;6(7):487-8 [18654114.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):365-77 [18692687.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6803-9 [18701506.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2756-62 [12829593.001]
  • [Cites] Br J Haematol. 2004 Feb;124(3):275-88 [14717774.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3915-20 [15007164.001]
  • [Cites] Leukemia. 2004 Apr;18(4):693-702 [15044926.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1153-6 [15057249.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Jul 15;104(2):307-13 [14982869.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1611-6 [15356655.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Ann Med. 2004;36(7):492-503 [15513300.001]
  • [Cites] Cancer Genet Cytogenet. 1981 Oct;4(2):111-37 [6949628.001]
  • [Cites] Blood. 1986 Feb;67(2):415-20 [3455828.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 15;40(2):171-85 [2766242.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1327-33 [1311214.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Mar;9(3):186-91 [7515661.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Leukemia. 1996 Feb;10(2):213-24 [8637229.001]
  • (PMID = 19825449.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA101140-019001; United States / NCI NIH HHS / CA / CA016058-34; United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / P30 CA016058-34; United States / NCI NIH HHS / CA / CA101140-019001; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  • [Other-IDs] NLM/ NIHMS132175; NLM/ PMC3607311
  •  go-up   go-down


23. Yamamoto M, Kakihana K, Ohashi K, Yamaguchi T, Tadokoro K, Akiyama H, Sakamaki H: Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Int J Hematol; 2009 May;89(4):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.
  • We recently developed an Invader assay combined with reverse transcriptase polymerase-chain-reaction in order to quantify T315I bcr-abl transcripts.
  • Using this assay, we serially monitored T315I bcr-abl transcripts in chronic myeloid leukemia (CML) patients whose bcr-abl transcripts were still detectable at 6 months after starting imatinib therapy.
  • In contrast, in a case of Philadelphia chromosome-positive acute lymphoid leukemia being treated with chemotherapy including imatinib, we monitored both wild-type and T315I bcr-abl transcripts, and found increased levels of T315I transcripts during relapse (0% at the time of diagnosis and 54.8% at relapse).
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Mutation / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jul 1;108(1):28-37 [16522812.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7374-9 [17189410.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2128-37 [15914554.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1321-31 [15215876.001]
  • [Cites] Mol Diagn. 1999 Dec;4(4):353-64 [10671646.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2190-6 [12399961.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4005-11 [17785585.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1007-14 [16424036.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Hematology. 2001;6(4):261-5 [27414845.001]
  • [Cites] Blood. 2007 Jan 15;109(2):500-2 [16990603.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1073-7 [16038734.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8272-7 [10890904.001]
  • [Cites] Haematologica. 2008 Feb;93(2):186-92 [18223278.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2332-8 [16772610.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2926-32 [15256429.001]
  • [Cites] Blood. 2008 Jul 1;112(1):53-5 [18403620.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4611-4 [12576318.001]
  • [Cites] Clin Biochem. 2004 Apr;37(4):268-76 [15003728.001]
  • [Cites] N Engl J Med. 2003 May 29;348(22):2265-6 [12773665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400 [15705718.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):92-9 [16343892.001]
  • (PMID = 19343480.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


24. Huisman J, Aukema EJ, Deijen JB, van Coeverden SC, Kaspers GJ, van der Pal HJ, Delemarre-van de Waal HA: The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study. BMC Pediatr; 2008;8:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study.
  • BACKGROUND: To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse.
  • [MeSH-major] Cognition / drug effects. Human Growth Hormone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Survivors / psychology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Protoc. 2006;1(2):892-9 [17406322.001]
  • [Cites] Acta Psychiatr Scand. 2007 Feb;115(2):114-25 [17244175.001]
  • [Cites] Growth Horm IGF Res. 2000 Apr;10 Suppl B:S69-73 [10984257.001]
  • [Cites] J Pediatr. 2001 Sep;139(3):413-20 [11562622.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Curr Probl Cancer. 2003 Jul-Aug;27(4):177-97 [12855950.001]
  • [Cites] Psychoneuroendocrinology. 2004 Aug;29(7):839-50 [15177699.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Jan;40(1):111-6 [8306469.001]
  • [Cites] Psychoneuroendocrinology. 1996 Apr;21(3):313-22 [8817729.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2826-35 [8874345.001]
  • [Cites] Psychoneuroendocrinology. 1998 Jan;23(1):45-55 [9618751.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):471-5 [10022403.001]
  • [Cites] Arq Neuropsiquiatr. 1999 Jun;57(2A):182-9 [10412515.001]
  • [Cites] J Pediatr Psychol. 2005 Jan-Feb;30(1):51-63 [15610985.001]
  • [Cites] J Pediatr Psychol. 2005 Jan-Feb;30(1):65-78 [15610986.001]
  • [Cites] Arch Clin Neuropsychol. 2005 May;20(3):409-16 [15797176.001]
  • [Cites] Horm Res. 2005;63(6):300-4 [16020938.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):258-61 [16369923.001]
  • [Cites] Cancer. 2006 May 1;106(9):2067-75 [16568441.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Nov;65(5):617-25 [17054463.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):3-12 [10687723.001]
  • (PMID = 18570650.001).
  • [ISSN] 1471-2431
  • [Journal-full-title] BMC pediatrics
  • [ISO-abbreviation] BMC Pediatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2447830
  •  go-up   go-down


25. Zunino SJ, Storms DH, Ducore JM: Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett; 2010 Oct 1;296(1):49-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).
  • Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse.
  • Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Leuk Lymphoma. 2005 May;46(5):681-91 [16019505.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7 [19034447.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4100-8 [12010813.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Dec 30;141(3):956-62 [2880583.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):393-8 [2891436.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1597-600 [2595371.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3658-61 [8101765.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):275-83 [8199015.001]
  • [Cites] Blood. 1996 May 1;87(9):3892-8 [8611717.001]
  • [Cites] Leukemia. 1996 Mar;10(3):558-63 [8642875.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1135-46 [8695830.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4332-7 [8813118.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2015-9 [9292537.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Crit Rev Clin Lab Sci. 1998 Feb;35(1):1-57 [9532418.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):875-93 [17671794.001]
  • (PMID = 20381955.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA122117; United States / NCI NIH HHS / CA / 1R21CA122117-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  • [Other-IDs] NLM/ NIHMS195255; NLM/ PMC2906616
  •  go-up   go-down


26. Ganesan P, Thulkar S, Gupta R, Bakhshi S: Childhood aleukemic leukemia with hypercalcemia and bone lesions mimicking metabolic bone disease. J Pediatr Endocrinol Metab; 2009 May;22(5):463-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood aleukemic leukemia with hypercalcemia and bone lesions mimicking metabolic bone disease.
  • He was initially diagnosed with metabolic bone disease, and the hypercalcemia responded to treatment with intravenous hydration and bisphosphonates.
  • The only hematological abnormality was moderate anemia, which prompted bone marrow studies leading to a diagnosis of acute lymphoblastic leukemia (ALL).
  • We discuss the diagnostic challenges of this rare entity of aleukemic leukemia with hypercalcemia and lytic bone lesions, and review all the previously reported pediatric literature.
  • [MeSH-major] Hypercalcemia / etiology. Osteolysis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Blood Cell Count. Bone Density Conservation Agents / therapeutic use. Bone Diseases, Metabolic / blood. Bone Diseases, Metabolic / complications. Bone Diseases, Metabolic / drug therapy. Bone Diseases, Metabolic / pathology. Diagnosis, Differential. Diphosphonates / therapeutic use. Drug Therapy. Humans. Male. Parathyroid Hormone / blood. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618667.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Parathyroid Hormone
  •  go-up   go-down


27. Park AH, Muntz HR, Smith ME, Afify Z, Pysher T, Pavia A: Pediatric invasive fungal rhinosinusitis in immunocompromised children with cancer. Otolaryngol Head Neck Surg; 2005 Sep;133(3):411-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventeen consecutive pediatric immunocompromised patients with hematologic and lymphoid neoplasms underwent nasal endoscopy and biopsy for possible FS.
  • Eight patients had acute myelogenous leukemia (AML); 6 patients had acute lymphoblastic leukemia (ALL); 1 patient had Burkitt's lymphoma, 1 patient had undifferentiated leukemia; and 1 patient had biphenotypic acute leukemia.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Sinusitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143192.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Lee JI, Park HJ, Oh ST, Lee JY, Cho BK: A case of leukemia cutis at the site of a prior catheter insertion. Ann Dermatol; 2009 May;21(2):193-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of leukemia cutis at the site of a prior catheter insertion.
  • Leukemia cutis is the cutaneous involvement of leukemic neoplastic cells.
  • It is an uncommon feature of systemic leukemia, and is associated with a poor prognosis.
  • The history was significant for acute lymphoblastic leukemia (ALL) for 4 years; an allogenic bone marrow transplantation was performed 3 years earlier.
  • Herein we report a case of leukemia cutis at the site of a prior catheter insertion in a patient with ALL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2005 Jan;75(1):54-6 [15732436.001]
  • [Cites] Semin Dermatol. 1994 Sep;13(3):223-30 [7986692.001]
  • [Cites] J Dermatol. 1991 May;18(5):281-5 [1939854.001]
  • [Cites] Arch Dermatol. 1987 Jan;123(1):88-90 [3467659.001]
  • [Cites] J Am Acad Dermatol. 1984 Jul;11(1):121-8 [6736347.001]
  • [Cites] Blood. 1972 Jul;40(1):52-61 [4504250.001]
  • [Cites] Cancer. 1967 Jan;20(1):23-30 [6016870.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):237-8 [15270902.001]
  • [Cites] Am J Hematol. 2003 Apr;72(4):274-7 [12666140.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2002 Mar;16(2):177-8 [12046831.001]
  • [Cites] Haematologica. 2000 Jul;85(7):758-62 [10897129.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Jul;32(1):171-3 [17468005.001]
  • (PMID = 20523785.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2861221
  • [Keywords] NOTNLM ; Acute lymphocytic leukemia / Leukemia cutis / Site of catheter insertion
  •  go-up   go-down


29. Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, Klingebiel T, Stary J, Felice MS, Magyarosy E, Schrappe M, Dini G, Gadner H, Valsecchi MG: Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica; 2008 Jun;93(6):925-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time.
  • The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial.
  • Of 357 pediatric patients with very-high-risk acute lymphoblastic leukemia, 259 received chemotherapy, 55 transplantation from compatible related and 43 from unrelated donors.
  • The 5-year disease-free survival was 44.2% overall and 42.5% for chemotherapy only patients.
  • The chemotherapy conditional 5-year disease-free survival increased to 44.4%, 47.6%, 51.7%, and 60.4% in patients who maintained their first remission for at least 3, 6, 9, and 12 months respectively.
  • The relative advantage of transplant from compatible related donors in very-high-risk childhood acute lymphoblastic leukemia was consistent for any time elapsed in first remission.
  • [MeSH-major] Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Cohort Studies. Disease-Free Survival. Humans. Immunophenotyping. Prospective Studies. Remission Induction. Risk. Time Factors. Translocation, Genetic. Treatment Outcome


30. Hou X, Wang S, Zhou Y, Xu Z, Zou Y, Zhu X, Han M, Pang T, Han ZC: Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol; 2005 Oct;82(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
  • Cyclin D1 is a key protein involved in cell cycle regulation.
  • Correlation between genetic polymorphism of A870G of CCND1 and clinical outcome among patients with acute lymphoblastic leukemia (ALL) has been reported.
  • Stratification of patients according to cell type, risk level, and chemotherapeutic response showed significance for the AA genotype in T-cell ALL, ALL with high risk, and no complete remission (P = .047, P = .011, and P = .007, respectively).
  • [MeSH-major] Cyclin D1 / genetics. Exons / genetics. Genetic Predisposition to Disease. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


31. Bonnet M, Sizaire V, Kebede Y, Janin A, Doshetov D, Mirzoian B, Arzumanian A, Muminov T, Iona E, Rigouts L, Rüsch-Gerdes S, Varaine F: Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis; 2005 Oct;9(10):1147-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries.
  • SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance.
  • OBJECTIVE: To discuss the relevance of the DOTS strategy in settings with a high prevalence of drug resistance.
  • DESIGN: Retrospective analysis of one-year treatment outcomes of short-course chemotherapy (SCC) and results of drug susceptibility testing (DST) surveys of six programmes located in the former Soviet Union: Kemerovo prison, Russia; Abkhasia, Georgia; Nagorno-Karabagh, Azerbaijan; Karakalpakstan, Uzbekistan; Dashoguz Velayat, Turkmenistan; and South Kazakhstan Oblast, Kazakhstan.
  • Results are reported for new and previously treated smear-positive patients.
  • RESULTS: Treatment outcomes of 3090 patients and DST results of 1383 patients were collected.
  • Treatment success rates ranged between 87% and 61%, in Nagorno-Karabagh and Kemerovo, respectively, and failure rates between 7% and 23%.
  • Any drug resistance ranged between 66% and 31% in the same programmes.
  • MDR rates ranged between 28% in Karakalpakstan and Kemerovo prison and 4% in Nagorno-Karabagh.
  • CONCLUSION: These results show the limits of SCC in settings with a high prevalence of drug resistance.
  • They demonstrate that adapting treatment according to resistance patterns, access to reliable culture, DST and good quality second-line drugs are necessary.
  • [MeSH-major] Antitubercular Agents / administration & dosage. Directly Observed Therapy / standards. Tuberculosis, Multidrug-Resistant / drug therapy
  • [MeSH-minor] Confidence Intervals. Female. Humans. Male. Odds Ratio. Prevalence. Retrospective Studies. Treatment Outcome. USSR / epidemiology

  • Genetic Alliance. consumer health - Tuberculosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Tuberc Lung Dis. 2005 Oct;9(10):1061 [16229215.001]
  • (PMID = 16229227.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


32. Bellingham GA, Kribs S, Kornecki A, Scott L, Leaker M, Fraser DD: Proximal splenic artery embolization in the management of splenic rupture. Pediatr Crit Care Med; 2009 Jan;10(1):e1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEASUREMENTS AND MAIN RESULTS: An 8-yr-old boy presented with abdominal pain radiating to the left shoulder 9 days after completing induction chemotherapy for acute lymphoblastic leukemia.
  • [MeSH-major] Embolization, Therapeutic / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Artery. Splenic Rupture / etiology. Splenic Rupture / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131863.001).
  • [ISSN] 1529-7535
  • [Journal-full-title] Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
  • [ISO-abbreviation] Pediatr Crit Care Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


33. Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED: Tissue microarrays: one size does not fit all. Diagn Pathol; 2010 Jul 07;5:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A simulated TMA with between 1 and 10 cores was designed to study tumor expression of 6 biomarkers with varied expression patterns (B7-H1, B7-H3, survivin, Ki-67, CAIX, and IMP3) using 100 patients with clear cell renal cell carcinoma (RCC).

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Biometrics. 1989 Mar;45(1):255-68 [2720055.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4 [16106022.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Dec;1(2):104-11 [16264828.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3381-5 [16585157.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1697-702 [16670718.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):500-3 [16822874.001]
  • [Cites] J Pathol. 2000 Dec;192(4):549-53 [11113875.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1943-9 [11140706.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):146-9 [17635238.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):783-90 [17594714.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4757-64 [17947723.001]
  • [Cites] Lab Invest. 2007 Dec;87(12):1206-17 [17906661.001]
  • [Cites] Pathol Res Pract. 2008;204(3):175-83 [18180112.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1471-9 [18260086.001]
  • [Cites] Scand J Urol Nephrol. 2007;41(6):485-9 [17853046.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1176-84 [18538369.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5150-7 [18694993.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3043-50 [18990746.001]
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):76-82 [19047904.001]
  • [Cites] J Clin Pathol. 2009 Jul;62(7):629-33 [19318344.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):312-9 [11859202.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Expert Rev Mol Diagn. 2003 Jul;3(4):421-30 [12877382.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • (PMID = 20609235.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA134345-03; United States / NCI NIH HHS / CA / R01 CA134345; United States / NCI NIH HHS / CA / R01 CA134345-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2910003
  •  go-up   go-down


34. Lamb JR, Gibson NW: Complexity in common diseases: big biology for all. Sci Transl Med; 2010 Mar 31;2(25):25cm11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In response, we argue that true progress on the diagnosis and treatment of common human diseases will require the advent of big biology and its deep integration with focused research as practiced in both academic and industrial institutions.
  • [MeSH-major] Biomedical Research / methods. Biotechnology / methods. Disease. Medicine / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Sci Transl Med. 2010 Mar 24;2(24):24cm10 [20375005.001]
  • (PMID = 20424010.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood; 2009 Apr 30;113(18):4153-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
  • Clinical risk classification is inaccurate in predicting relapse in adult patients with acute lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate chemotherapy or stem cell transplantation (SCT).
  • We studied minimal residual disease (MRD) as a predictive factor for recurrence and as a decisional tool for postconsolidation maintenance (in MRD(neg)) or SCT (in MRD(pos)).
  • Five-year overall survival/disease-free survival rates were 0.75/0.72 in the MRD(neg) group compared with 0.33/0.14 in MRD(pos) (P = .001), regardless of the clinical risk class.
  • MRD results at weeks 16 to 22 correlated strongly with the earlier time point (P = .001) using a level of 10(-4) or higher to define persistent disease.
  • [MeSH-major] Neoplasm, Residual / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141862.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00358072
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


36. Yamashita T, Kodama Y, Tanaka M, Yamakiri K, Kawano Y, Sakamoto T: Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication. J Glaucoma; 2010 Mar;19(3):188-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication.
  • PURPOSE: To evaluate the ocular hypertensive response to repetitive cycles of high-dose systemic corticosteroid in young patients with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Dexamethasone / adverse effects. Glaucoma / chemically induced. Glucocorticoids / adverse effects. Intraocular Pressure / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


37. Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R: The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood; 2010 Apr 29;115(17):3570-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chromosomal translocation t(4;11)(q21;q23) is the most frequent genetic aberration of the human MLL gene, resulting in high-risk acute lymphoblastic leukemia (ALL).
  • Recipients of AF4.MLL- or double-transduced LSPCs developed pro-B ALL, B/T biphenotypic acute leukemia, or mixed lineage leukemia.
  • Transplantation of MLL.AF4- or mock-transduced LSPCs did not result in disease development during an observation period of 13 months.
  • These findings indicate that the expression of the AF4.MLL fusion protein is capable of inducing acute lymphoblastic leukemia even in the absence of the MLL.AF4 fusion protein.
  • In view of recent findings, these results may imply that t(4;11) leukemia is based on 2 oncoproteins, providing an explanation for the very early onset of disease in humans.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Leukemic. Myeloid-Lymphoid Leukemia Protein / metabolism. Nuclear Proteins / metabolism. Oncogene Proteins, Fusion / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194896.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aff1 protein, mouse; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Mll protein, mouse
  •  go-up   go-down


38. Tsuji A, Sasaki M, Ishii T, Sato S, Kanki H, Suzuki S, Takeuchi S, Fukuda T: Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease? Keio J Med; 2010;59(2):64-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease?
  • This report describes the long-term (23 years) follow-up of a pediatric patient with acute lymphoblastic leukemia and eosinophilia who underwent multiple valve replacements.
  • An 8-year-old boy with this complex disease was admitted in January 1984 and treated with 6-week course of vincristine, L-asparaginase, and prednisolone, which induced complete remission.
  • The present study indicates that a subset of patients in complete remission of acute lymphoblastic leukemia and eosinophilia can show persistent myocardial eosinophilic infiltration and are at risk of late cardiac disease.
  • [MeSH-major] Cardiomyopathies / etiology. Cardiomyopathies / pathology. Eosinophilia / complications. Eosinophilia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


39. Santos FR, Kozasa EH, Chauffaille Mde L, Colleoni GW, Leite JR: Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. J Psychosom Res; 2006 May;60(5):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aims to investigate the prevalence of posttraumatic stress disorder (PTSD) symptoms, anxiety, and depression in patients with hematological malignancies, and to investigate the possible relationship between these symptoms and variables such as demographic data, social support, and quality of life (QOL).
  • We studied 107 patients: 54 with non-Hodgkin's lymphoma (NHL), 18 acute myelogenous leukaemia (AML), 10 acute lymphoblastic leukaemia (ALL), and 25 multiple myeloma (MM).
  • Patients with recent diagnosis had a level of intrusion symptoms (IES) relevantly higher than the others.
  • [MeSH-major] Adaptation, Psychological. Leukemia / psychology. Quality of Life

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16650591.001).
  • [ISSN] 0022-3999
  • [Journal-full-title] Journal of psychosomatic research
  • [ISO-abbreviation] J Psychosom Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. D'Achille P, Seymour JF, Campbell LJ: Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet; 2006 Nov;171(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.
  • We present a series of 12 cases of de novo acute lymphoblastic leukemia (ALL) with translocation t(14;18)(q32;q21).
  • The median age of patients at presentation was 65.5 years, and no patient presented with a past history or any clinical evidence of lymphoma.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074591.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Sialic Acid Binding Ig-like Lectin 2; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 32
  •  go-up   go-down


41. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC: Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia; 2009 Oct;23(10):1763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
  • The aim of this prospective study was to investigate the feasibility of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) in 37 adults with high-risk acute lymphoblastic leukemia (ALL) in first (n=30) or second (n=7) complete remission (CR).
  • Graft-versus-host disease (GVHD) prophylaxis consisted of calcineurin inhibitor (cyclosporine for sibling and tacrolimus for unrelated transplants) and methotrexate.
  • The cumulative incidence of acute (grades II-IV) and chronic GVHD was 43.2 and 65.6%, respectively.
  • After a median follow-up of 36 months for surviving transplants, the 3-year relapse, non-relapse mortality, disease-free survival and overall survival rates were 19.7, 17.7, 62.6 and 64.1%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Feasibility Studies. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Melphalan / administration & dosage. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440217.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


42. Dasatinib: BMS 354825. Drugs R D; 2006;7(2):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired resistance/intolerance.
  • While imatinib remains a frontline therapy for CML, patients with advanced disease frequently develop resistance to imatinib therapy through multiple mechanisms.
  • In December 2005, Bristol-Myers Squibb announced that it has completed the rolling NDA submission to the US FDA for dasatinib in the treatment of CML in chronic, accelerated or blast phases, as well as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) in patients with resistance or intolerance to prior treatment.
  • In in vitro assays, dasatinib induced apoptosis and had potent activity in the imatinib-resistant tumour cells lines and CML patient specimens.
  • [MeSH-minor] Animals. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Dasatinib. Fusion Proteins, bcr-abl / metabolism. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542059.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


43. Karanth M, Taniere P, Barraclough J, Murray JA: A rare presentation of zygomycosis (mucormycosis) and review of the literature. J Clin Pathol; 2005 Aug;58(8):879-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report describes a 56 year old woman who developed this infection while receiving chemotherapy for acute lymphoblastic leukaemia.
  • Medical and surgical measures proved unsuccessful because there was a delay in diagnosis and institution of appropriate treatment.
  • [MeSH-major] Intestinal Diseases / diagnosis. Mucormycosis / diagnosis. Opportunistic Infections / diagnosis
  • [MeSH-minor] Female. Humans. Immunocompromised Host. Middle Aged. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Zygomycosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):129-31 [10882261.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):331-6 [9375750.001]
  • [Cites] Mycoses. 2001;44(7-8):253-60 [11714058.001]
  • [Cites] J Antimicrob Chemother. 2001 Dec;48(6):919-21 [11733480.001]
  • [Cites] Antimicrob Agents Chemother. 2002 May;46(5):1581-2 [11959605.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2 [12069997.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • [Cites] Mycoses. 2002;45 Suppl 3:56-60 [12690973.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Dec;22(12):753-6 [14605941.001]
  • [Cites] Clin Microbiol Infect. 2004 Mar;10 Suppl 1:31-47 [14748801.001]
  • [Cites] Haematologica. 2004 Feb;89(2):207-14 [15003897.001]
  • [Cites] J Perinatol. 2004 May;24(5):319-21 [15116129.001]
  • [Cites] Scand J Infect Dis. 1990;22(4):499-501 [2218411.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):952-4 [1913115.001]
  • [Cites] Ann Thorac Surg. 1994 Apr;57(4):1044-50 [8166512.001]
  • [Cites] Clin Infect Dis. 1995 Mar;20(3):617-20 [7756485.001]
  • [Cites] Haematologica. 2000 Oct;85(10):1068-71 [11025599.001]
  • (PMID = 16049294.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC1770885
  •  go-up   go-down


44. Al-Anazi K, Al-Jasser A: Candidaemia in patients with haematological disorders and stem cell transplant. Libyan J Med; 2006 Nov 21;1(2):140-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidaemia in patients with haematological disorders and stem cell transplant.
  • The incidence of non-albicans species of Candida has recently increased, especially in patients with malignant haematological disorders receiving fluconazole prophylaxis.
  • The most frequent underlying haematological disorders were acute myeloid leukaemia (AML) followed by acute lymphoblastic leukaemia (ALL).
  • The main predisposing factors for the development of candidaemia were: broad spectrum antibiotics, central venous catheters, neutropenia, cytotoxic chemotherapy, coexisting bacterial infections, steroid therapy, relapsing or untreated primary disease and fluconazole prophylaxis.Eight episodes were complicated by chronic disseminated candidiasis.
  • The highest mortality rate was encountered with C.tropicalis infections.Candidaemia is an important cause of mortality and morbidity in patients with malignant haematological disorders and stem cell transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mycoses. 2003;46(9-10):390-6 [14622387.001]
  • [Cites] J Hosp Infect. 2002 Apr;50(4):243-60 [12014897.001]
  • [Cites] Med Mycol. 2003 Dec;41(6):521-8 [14725327.001]
  • [Cites] Infect Control Hosp Epidemiol. 2004 Jan;25(1):60-4 [14756222.001]
  • [Cites] Saudi Med J. 2004 May;25(5):566-9 [15138521.001]
  • [Cites] Epidemiol Infect. 2004 Dec;132(6):1175-80 [15635977.001]
  • [Cites] New Microbiol. 2004 Oct;27(4):407-10 [15646057.001]
  • [Cites] J Clin Microbiol. 1996 Aug;34(8):1918-21 [8818881.001]
  • [Cites] Support Care Cancer. 1997 May;5(3):249-51 [9176973.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Clin Infect Dis. 1999 May;28(5):1071-9 [10452637.001]
  • [Cites] J Antimicrob Chemother. 1999 Aug;44(2):151-62 [10473222.001]
  • [Cites] Eur J Haematol. 1999 Aug;63(2):77-85 [10480286.001]
  • [Cites] J Infect Dis. 2000 Jan;181(1):309-16 [10608780.001]
  • [Cites] Arch Intern Med. 2000 Sep 25;160(17):2659-64 [10999981.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1349-53 [11745210.001]
  • [Cites] J Antimicrob Chemother. 2002 Feb;49 Suppl 1:3-6 [11801574.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Mar;21(3):209-11 [11957023.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):297-304 [12183145.001]
  • [Cites] Mycoses. 2003 Sep;46(8):293-8 [12950897.001]
  • [Cites] Haematologica. 2004 Mar;89(3):378-80 [15020289.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3142-6 [15243073.001]
  • [Cites] Drugs. 2004;64(18):1997-2020 [15341494.001]
  • [Cites] Mycoses. 1994;37 Suppl 2:52-5 [7609744.001]
  • [Cites] Clin Infect Dis. 1997 Jun;24(6):1122-8 [9195068.001]
  • [Cites] Am J Med. 1998 Mar;104(3):238-45 [9552086.001]
  • [Cites] Blood Rev. 1998 Dec;12(4):241-54 [9950095.001]
  • [Cites] Am J Med. 2002 Apr 1;112(5):380-5 [11904112.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):40-6 [11918531.001]
  • [Cites] Haematologica. 2002 May;87(5):535-41 [12010669.001]
  • [Cites] Clin Infect Dis. 2004 Jan 15;38(2):161-89 [14699449.001]
  • (PMID = 21526012.001).
  • [ISSN] 1993-2820
  • [Journal-full-title] The Libyan journal of medicine
  • [ISO-abbreviation] Libyan J Med
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3081354
  • [Keywords] NOTNLM ; Candida / acute lymphoblastic leukaemia / acute myeloid leukaemia / chronic disseminated candidiasis / stem cell transplant
  •  go-up   go-down


45. Chowdhury S, Bandyopadhyay S, Mandal C, Chandra S, Mandal C: Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study. BMC Cancer; 2008;8:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
  • BACKGROUND: Over expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac2-GPs, abbreviated as OAcSGP) has been demonstrated as a disease-associated antigen on the lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • Exploring this affinity, enhanced expression of OAcSGP was observed, at the onset of disease, followed by its decrease with chemotherapy and reappearance with relapse.
  • In spite of treatment, patients retain the diseased cells referred to as minimal residual disease (MRD) responsible for relapse.
  • Our aim was to select a suitable template by using the differential expression of OAcSGP along with other known CD antigens to monitor MRD in peripheral blood (PB) and bone marrow (BM) of Indian patients with B- or T-ALL during treatment and correlate it with the disease status.
  • METHODS: A two-year longitudinal follow-up study was done with 109 patients from the onset of the disease till the end of chemotherapy, treated under MCP841protocol.
  • Hence, MRD study beyond two-years follow-up is necessary to investigate further reduction in MRD, thereby ensuring their disease-free survival.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Sialoglycoproteins / metabolism
  • [MeSH-minor] Adolescent. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Child. Child, Preschool. Disease-Free Survival. Female. Flow Cytometry. Follow-Up Studies. Humans. Infant. Longitudinal Studies. Male. Monitoring, Physiologic. Neoplasm, Residual. Remission Induction. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1570-83 [16026693.001]
  • [Cites] Curr Opin Pharmacol. 2005 Aug;5(4):431-7 [15955740.001]
  • [Cites] Glycobiology. 2006 Jan;16(1):1R-27R [16014749.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):769-70 [16886283.001]
  • [Cites] Indian J Biochem Biophys. 2006 Feb;43(1):7-14 [16955745.001]
  • [Cites] Glycobiology. 2000 Jun;10(6):539-49 [10814695.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):801-12 [11054061.001]
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):1-19 [11987913.001]
  • [Cites] Glycoconj J. 2001 Jul;18(7):529-37 [12151714.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] J Infect Dis. 2004 Apr 1;189(7):1257-64 [15031795.001]
  • [Cites] Clin Biochem. 2004 May;37(5):395-403 [15087256.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):270-7 [15197782.001]
  • [Cites] Glycobiology. 2004 Oct;14(10):859-70 [15190007.001]
  • [Cites] Science. 1984 Aug 24;225(4664):844-6 [6206564.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Biochem J. 1988 Aug 15;254(1):195-202 [3140796.001]
  • [Cites] Biochem J. 1989 Jan 1;257(1):65-71 [2920028.001]
  • [Cites] Experientia. 1990 May 15;46(5):433-41 [2189746.001]
  • [Cites] Carbohydr Res. 1995 Mar 1;268(1):115-25 [7736461.001]
  • [Cites] Immunol Lett. 1997 Dec;59(3):151-7 [9419022.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):119-25 [10049046.001]
  • [Cites] Leukemia. 1999 Feb;13(2):309-12 [10025909.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):167-76 [10093685.001]
  • [Cites] Leuk Res. 1999 May;23(5):433-9 [10374857.001]
  • [Cites] Leuk Res. 1999 Sep;23(9):803-9 [10475619.001]
  • [Cites] J Infect Dis. 2004 Dec 1;190(11):2010-9 [15529267.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):35-41 [15606547.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):177-91 [15629900.001]
  • [Cites] J Immunol Methods. 2005 Feb;297(1-2):13-26 [15777927.001]
  • [Cites] J Cell Biochem. 2005 May 1;95(1):206-16 [15770663.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):623-34 [15704219.001]
  • (PMID = 18241334.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Sialoglycoproteins
  • [Other-IDs] NLM/ PMC2268943
  •  go-up   go-down


46. Kubiak-Wlekły A, Niemir ZI: [The involvement of neprilysin in the pathogenesis of glomerulopathies]. Pol Merkur Lekarski; 2009 Sep;27(159):239-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neprilysin (NEP, CD10, CALLA-common acute lymphoblastic leukaemia antigen, neutral endopeptidase, enkephalinase) is a zinc-dependent metallopeptidase, which is the first podocytic antigen, which has been shown to induce human membranous glomerulonephritis (GN).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827739.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 13
  •  go-up   go-down


47. Fuster JL, Bermúdez M, Galera A, Llinares ME, Calle D, Ortuño FJ: Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica; 2007 Dec;92(12):1723-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • The role of imatinib in childhood Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) has not been established.
  • We treated four children with imatinib in combination with conventional chemotherapy (CT) before stem cell transplantation (SCT).
  • Response evaluation consisted of fluorocytometric analysis of minimal residual disease (MRD) and standard qualitative RT-PCR follow-up.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / administration & dosage. Stem Cell Transplantation
  • [MeSH-minor] Benzamides. Child. Child, Preschool. Disease-Free Survival. Female. Flow Cytometry. Humans. Imatinib Mesylate. Male. Neoplasm Staging. Neoplasm, Residual. Prognosis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056006.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


48. Lazic J, Tosic N, Dokmanovic L, Krstovski N, Rodic P, Pavlovic S, Janic D: Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia. Med Oncol; 2010 Jun;27(2):449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia.
  • Contemporary protocols ensure high-remission rate and long-term free survival in children with acute lymphoblastic leukemia (ALL), but small percentage of patients is still incurable.
  • Molecular genetic methods helped to establish submicroscopic classification as well as minimal residual disease follow-up, considered to be responsible for relapse.
  • Our study enrolled 70 pediatric patients with de novo ALL, analyzed using reverse transcriptase-polymerase chain reaction for the presence of four major risk-stratifying translocations (BCR/ABL, MLL/AF4, TEL/AML1, and E2A/PBX1).
  • Bone marrow samples were collected at diagnosis, at the end of induction phase, and after intensive chemotherapy with the aim to establish the correlation between chromosomal aberration, clinical features, and treatment response.
  • [MeSH-major] Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1985-9 [8609706.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1071-9 [11167742.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):278-80 [14752867.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):667-9 [10583273.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2659-65 [10753848.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 Mar;12(1):165-79 [17355221.001]
  • [Cites] Blood. 1991 Feb 1;77(3):440-7 [1991161.001]
  • [Cites] Leuk Res. 1998 Jan;22(1):77-80 [9585083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Leuk Res. 1996 May;20(5):441-3 [8683984.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4275-83 [15156184.001]
  • [Cites] Blood. 1998 Feb 1;91(3):1021-8 [9446665.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1518-22 [18455790.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 1997 Jul 15;90(2):571-7 [9226156.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1075-80 [8562932.001]
  • [Cites] Leukemia. 2007 Apr;21(4):642-6 [17287854.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):585 [17762503.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):55-9 [9760154.001]
  • [Cites] Med Pediatr Oncol. 1999 Jun;32(6):455-6 [10358709.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):489-500 [16098062.001]
  • (PMID = 19488866.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


49. Schindler JW, Van Buren D, Foudi A, Krejci O, Qin J, Orkin SH, Hock H: TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell; 2009 Jul 2;5(1):43-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia.
  • The initial steps in the pathogenesis of acute leukemia remain incompletely understood.
  • The TEL-AML1 gene fusion, the hallmark translocation in Childhood Acute Lymphoblastic Leukemia and the first hit, occurs years before the clinical disease, most often in utero.
  • TEL-AML1 renders mice prone to malignancy after chemical mutagenesis when expressed in hematopoietic stem cells (HSCs), but not in early lymphoid progenitors.
  • We reveal that TEL-AML1 markedly increases the number of HSCs and predominantly maintains them in the quiescent (G(0)) stage of the cell cycle.
  • [MeSH-major] Bone Marrow Cells / metabolism. Core Binding Factor Alpha 2 Subunit / genetics. Hematopoietic Stem Cells / metabolism. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Oncogenes


50. Gruhn B, Taub JW, Ge Y, Beck JF, Zell R, Häfer R, Hermann FH, Debatin KM, Steinbach D: Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia; 2008 Sep;22(9):1692-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy.
  • Recent studies with very small numbers of patients showed that in some cases of childhood acute lymphoblastic leukemia (ALL), preleukemic cells are detectable on Guthrie cards that were used for newborn screening.
  • Positive screening cards were not associated with patient's age at diagnosis but were almost always found in patients with hyperdiploidy (10/11; 91%; P=0.04).
  • In conclusion, the majority of childhood B-precursor ALL arise prior to birth.
  • In the search for causes of childhood leukemia we should concentrate on prenatal factors as well as postnatal factors.
  • Our results suggest that autologous cord bloods could be a poor choice as the source of stem cells for transplantation in leukemia, which may contain preleukemic cells.
  • Pending the development of suitable methods, childhood leukemia is a potentially screenable disease.
  • [MeSH-major] Aneuploidy. Birth Weight. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Preleukemia / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains. Infant. Infant, Newborn. Male. Neonatal Screening. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / etiology. Retrospective Studies


51. Ruiz-Argüelles GJ, Fernández-Lara D, Estrada-Gómez R, Manzano C, Ruiz-Delgado GJ, Pérez-Romano B, Ruiz-Argüelles A: Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol; 2007;13(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
  • Two main techniques are being used for the detection of minimal residual disease (MRD) in acute leukemia (AL): immunophenotypic analysis and polymerase chain reaction (PCR).
  • (1) acute lymphoblastic leukemia (ALL) patients with MRD (n = 36);.
  • (2) acute myeloblastic leukemia (AML) patients with MRD (n = 13);.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Neoplasm Recurrence, Local / blood. Neoplasm, Residual / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353179.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


52. Kern W, Kohlmann A, Schoch C, Schnittger S, Haferlach T: Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. Cancer; 2006 Nov 15;107(10):2401-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
  • BACKGROUND: Microarray analysis is considered a future diagnostic tool in leukemias.
  • Whereas data accumulate on specific gene expression patterns in biologically defined leukemia entities, data on the correlation between flow cytometrically determined protein expression, which are essential in the diagnostic setting today, and microarray results are limited.
  • METHODS: The results obtained by microarray analysis were compared using the Affymetrix GeneChip HG-U133 system in parallel with flow cytometric findings of 36 relevant targets in 814 patients with newly diagnosed acute and chronic leukemias as well as in normal bone marrow samples.
  • RESULTS: In a total of 21,581 individual comparisons between signal intensities obtained by microarray analysis and percentages of positive cell as determined by flow cytometry, coefficients of correlation in the range of 0.171 to 0.807 were obtained.
  • They are in favor of a future application of the microarray technology as a robust diagnostic tool in leukemias.
  • [MeSH-major] Antigens, Surface / analysis. Biomarkers, Tumor / analysis. Immunophenotyping. Leukemia / diagnosis. Microarray Analysis. Molecular Diagnostic Techniques / methods. RNA, Messenger / analysis
  • [MeSH-minor] Antigens, CD / analysis. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Flow Cytometry. Gene Expression Profiling. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041886.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


53. Wu M, Sun XF, Xu ZM, Zhang XY, Li FR, Wang XG, Chen XL, Lin HQ, Wen HG, Sun X, Song TW: [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug;13(4):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
  • To test the European BIOMED-1 Concerted Action proposed technique to detect minimal residual disease (MRD) in the chinese patients with precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) by triple-staining flow cytometry and to define both normal and aberrant phenotypic profiles of precursor B cells, a series of bone marrow samples, 35 from precursor-B-ALL (13 in newly diagnosed cases, 15 at the end of remission induction therapy and 7 at end of the consolidations), and 19 from normal controls, were immunophenotyped with the five triple-staining antibodies (TdT/CD10/CD19, CD10/CD20/CD19, CD34/CD38/CD19, CD34/CD22/CD19 and CD19/CD34/CD45) recom-mended by the BIOMED-1 using common flow cytometric protocols.
  • The results showed that three major CD19(+) cell subpopulations were identified in the normal controls, representing three consecutive maturation stages.
  • The subpopulations in the precursor-B-ALL cases disappeared and were replaced with a great number of luekemic cells which had different characteristics of phenotypes, and then they reappeared with almost same characteristics as the normal CD19(+) cells after the patients achieved complete remission.
  • When the five triple-staining antibody combinations were used, the phenotypic aberrancies could be identified in 12/13 (92.3%) cases with newly diagnosed precursor-B-ALL, at least one triple-labeling per case at the level of 0.01% or more.
  • At the end of remission induction, the phenotypic aberrancies could be detected in 5/15 (33.3%), of which, 3/8 (37.5%) cases with the leukemic phenotypes detected both at the newly diagnosis and at the end of induction.
  • It is concluded that the flow cytometric detection of precursor-B-ALL-MRD proposed by BIOMED-1 Concerted Action were well realized in this study.
  • The one precursor-B-ALL cell can be effectively detected out of 10(4) normal bone marrow cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129033.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


54. Karst C, Gross M, Haase D, Wedding U, Höffken K, Liehr T, Mkrtchyan H: Novel cryptic chromosomal rearrangements detected in acute lymphoblastic leukemia detected by application of new multicolor fluorescent in situ hybridization approaches. Int J Oncol; 2006 Apr;28(4):891-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel cryptic chromosomal rearrangements detected in acute lymphoblastic leukemia detected by application of new multicolor fluorescent in situ hybridization approaches.
  • However, it is often difficult to obtain good karyotypes, especially of cells from cases with acute lymphoblastic leukemia (ALL) because of poor morphology and spreading.
  • In summary, mMCB and subCTM were proven to be powerful methods in the screening for new cryptic chromosomal aberrations, which considerably increased the accuracy of cytogenetic diagnosis.
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Spectral Karyotyping / methods. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525638.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


55. Udayakumar AM, Bashir WA, Pathare AV, Wali YA, Zacharia M, Khan AA, Soliman H, Al-Lamki Z, Raeburn JA: Cytogenetic profile of childhood acute lymphoblastic leukemia in Oman. Arch Med Res; 2007 Apr;38(3):305-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic profile of childhood acute lymphoblastic leukemia in Oman.
  • BACKGROUND: Chromosomal abnormalities have important diagnostic and prognostic significance in acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


56. Bell W, Warner JT, Evans WD, Webb DK, Mullen RH, Gregory JW: Perception of effort at low and moderate intensity exercise in survivors of childhood acute lymphoblastic leukaemia. Ann Hum Biol; 2006 May-Jun;33(3):357-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perception of effort at low and moderate intensity exercise in survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: The study examined the degree to which male and female survivors of acute lymphoblastic leukaemia (ALL) perceive effort at low and moderate intensity exercise in association with related physiological variables.
  • [MeSH-major] Physical Exertion / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092872.001).
  • [ISSN] 0301-4460
  • [Journal-full-title] Annals of human biology
  • [ISO-abbreviation] Ann. Hum. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K, Reid GS: Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol; 2006 Feb;132(4):452-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and, although current therapy is widely effective, relapse remains a significant clinical problem for which new treatment strategies are required.
  • The ligation of Toll-like receptors (TLR) on antigen-presenting cells stimulates the generation of strong T-cell helper type 1 (Th1) adaptive immune responses.
  • Although TLR9 ligation has been shown to enhance immunogenicity of a number of leukaemia cell types, there have been few reports of the effects mediated through other TLR.
  • In this study we analysed both the expression of TLR by B-cell precursor ALL cell lines and the effects of individual TLR ligation on the ability of ALL cells to stimulate allogeneic T cells.
  • While ligation of TLR2, TLR 7 and TLR9 led to detectable changes in ALL costimulatory molecule expression, only TLR2 and TLR9 stimulation influenced T-cell responses.
  • The TLR2 ligand Pam3CysSerLys4 provoked the most significant changes in T-cell response, dramatically augmenting interferon-gamma production.
  • [MeSH-major] Immunotherapy / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Toll-Like Receptors / metabolism
  • [MeSH-minor] Antigens, CD40 / metabolism. Cell Line, Tumor. Cell Proliferation. Guanosine / analogs & derivatives. Guanosine / pharmacology. Humans. Interferon-gamma / immunology. Ligands. Peptidoglycan / pharmacology. Protein Binding. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Stimulation, Chemical. T-Lymphocytes, Helper-Inducer / immunology. Toll-Like Receptor 1 / metabolism. Toll-Like Receptor 2 / metabolism. Toll-Like Receptor 3 / metabolism. Toll-Like Receptor 4 / metabolism. Toll-Like Receptor 5 / metabolism. Toll-Like Receptor 7 / metabolism. Toll-Like Receptor 9 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412017.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Ligands; 0 / Peptidoglycan; 0 / RNA, Messenger; 0 / Toll-Like Receptor 1; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4; 0 / Toll-Like Receptor 5; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 12133JR80S / Guanosine; 82115-62-6 / Interferon-gamma; 9CAS0V66OI / loxoribine
  •  go-up   go-down


58. Ulusoy G, Adali O, Tumer TB, Sahin G, Gozdasoglu S, Arinç E: Significance of genetic polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia. Oncology; 2007;72(1-2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of genetic polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia.
  • BACKGROUND/AIMS: The molecular etiology of childhood acute lymphoblastic leukemia (ALL) is likely to involve interactions between environmental factors and genetic make up.
  • Understanding these interactions between various predisposing genes for the risk of developing childhood leukemia is of considerable importance.
  • [MeSH-major] Cytochrome P-450 CYP2E1 / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 18025800.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 1.14.13.- / Cytochrome P-450 CYP2E1
  •  go-up   go-down


59. Barr RD, Sala A: Osteonecrosis in children and adolescents with cancer. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):483-5; discussion 486
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteonecrosis is recognized increasingly as a complication of the treatment of cancer in young people, especially those with acute lymphoblastic leukemia and non-Hodgkin lymphoma, reflecting a probable pathogenetic role of steroid therapy.
  • The disorder affects weight-bearing joints predominantly.

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064641.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


60. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R: Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clin Cancer Res; 2005 Apr 15;11(8):2974-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
  • PURPOSE: t(12;21)(p13; q22), present in approximately 25% of pediatric precursor B-ALL, is highly sensitivity to L-asparaginase and the prognosis depends on the intensity of the treatment protocol.
  • This study analyzes the relationship between the mRNA expression of the genes and fusion products involved in t(12;21), in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, and long-term clinical outcome in t(12;21)+ acute lymphoblastic leukemia (ALL) patients.
  • EXPERIMENTAL DESIGN: Long-term clinical outcome in 45 t(12;21)+ ALL patients was related to mRNA expression of TEL, AML1, TEL-AML1, and AML1-TEL, determined by real-time quantitative PCR, and the in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 21 / genetics. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic
  • [MeSH-minor] Asparaginase / pharmacology. Cell Survival / drug effects. Child. Core Binding Factor Alpha 2 Subunit. DNA-Binding Proteins / genetics. Disease-Free Survival. Humans. In Situ Hybridization, Fluorescence. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Prednisolone / pharmacology. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ets. RNA, Messenger / genetics. RNA, Messenger / metabolism. Repressor Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Treatment Outcome. Vincristine / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837750.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 0 / TEL-AML1 fusion protein; 0 / Transcription Factors; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


61. Walenkamp AM, Boer IG, Bestebroer J, Rozeveld D, Timmer-Bosscha H, Hemrika W, van Strijp JA, de Haas CJ: Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia; 2009 Apr;11(4):333-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.
  • PURPOSE: Tumor cell migration and metastasis share many similarities with leukocyte trafficking, which is critically regulated by chemokines and their receptors.
  • RESULTS: Staphylococcal superantigen-like 10 was found to bind CXCR4 expressed on human T acute lymphoblastic leukemia, lymphoma, and cervical carcinoma cell lines.
  • It potently inhibited CXCL12-induced calcium mobilization and cell migration.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Movement / drug effects. Chemokine CXCL12 / metabolism. Neoplasms / immunology. Staphylococcus / immunology. Superantigens / pharmacology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Polymerase Chain Reaction. Receptors, CXCR4 / antagonists & inhibitors. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6994-7001 [15153520.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):545-53 [11736934.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 15;30(2):E9 [11788735.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Infect Immun. 2003 May;71(5):2827-38 [12704157.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1294-300 [12835717.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3833-9 [12839981.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1229 [14520351.001]
  • [Cites] J Exp Med. 2004 Mar 1;199(5):687-95 [14993252.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):189-94 [15064869.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Blood. 2004 Jul 15;104(2):550-7 [15054042.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62 [15385732.001]
  • [Cites] J Immunol. 2004 Nov 1;173(9):5704-11 [15494522.001]
  • [Cites] Br J Haematol. 1994 Jan;86(1):210-2 [8011534.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):969-74 [9120403.001]
  • [Cites] J Virol. 1999 Feb;73(2):1719-23 [9882387.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82 [9918823.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2299-307 [9973507.001]
  • [Cites] J Virol. 1999 Sep;73(9):7489-96 [10438838.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2020-7 [15542591.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2926-33 [15728504.001]
  • [Cites] Biochem Pharmacol. 2005 Sep 1;70(5):752-61 [16011832.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1824-30 [15905192.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):920-7 [16086019.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35760-6 [16107333.001]
  • [Cites] J Mol Biol. 2005 Nov 4;353(4):859-72 [16213522.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2026-9 [16671092.001]
  • [Cites] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3143-51 [16840734.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8017-26 [17114475.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3113-21 [17172414.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):478-83 [17362322.001]
  • [Cites] Br J Haematol. 2007 May;137(4):288-96 [17456052.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2936-43 [17132726.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2392-404 [17503430.001]
  • [Cites] Int J Hematol. 2007 Jun;85(5):390-6 [17562613.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):2989-98 [17709514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14759-64 [17804806.001]
  • [Cites] J Exp Med. 2007 Oct 1;204(10):2461-71 [17893203.001]
  • [Cites] Cancer Treat Res. 2007;135:177-84 [17953416.001]
  • [Cites] Mol Microbiol. 2007 Dec;66(6):1342-55 [18045383.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11821-9 [18089812.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1379-86 [18487549.001]
  • [Cites] J Leukoc Biol. 2008 Oct;84(4):1130-40 [18653785.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6215-24 [18955566.001]
  • [Cites] Stem Cells. 2001;19(5):443-52 [11553853.001]
  • (PMID = 19308288.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4; 0 / Superantigens
  • [Other-IDs] NLM/ PMC2657885
  •  go-up   go-down


62. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA, EUROCARE Working Group: Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer; 2009 Apr;45(6):992-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival improved significantly over time for acute lymphoid leukaemia and primitive neuroectodermal tumours in children and for non-Hodgkin lymphoma in adolescents/young adults.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231160.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Oberaigner W; Hackl M; Van Eycken E; Verstreken M; Holub J; Jurickova L; Storm HH; Engholm G; Hakulinen T; Belot A; Hédelin G; Velten M; Tron I; Le Gall E; Launoy G; Guizard AV; Faivre J; Bouvier AM; Carli PM; Maynadié M; Danzon A; Buemi A; Tretarre B; Lacour B; Desandes E; Colonna M; Molinié F; Bara S; Schvartz S; Ganry O; Grosclaude P; Brenner H; Kaatsch P; Ziegler H; Tryggvadottir L; Comber H; Berrino F; Allemani C; Baili P; Ciampichini R; Ciccolallo L; Gatta G; Micheli A; Sant M; Sowe S; Zigon G; Tagliabue G; Contiero P; Bellù F; Giacomin A; Ferretti S; Dal Maso DS; De Dottori M; De Paoli A; Zanier L; Vercelli M; Orengo MA; Casella C; Quaglia A; Pannelli F; Federico M; Rashid I; Cirilli C; Fusco M; Traina A; De Lisi V; Bozzani F; Magnani C; Pastore G; Tumino R; La Rosa MG; Spata E; Sigona A; Mangone L; Falcini F; Foca F; Giorgetti S; Senatore G; Iannelli A; Budroni M; Zanetti R; Patriarca S; Rosso S; Piffer S; Franchini S; Paci E; Crocetti E; La Rosa F; Stracci F; Cassetti T; Zambon P; Guzzinati S; Caldora M; Capocaccia R; Carrani E; De Angelis R; Francisci S; Grande E; Inghelmann R; Lenz H; Martina L; Roazzi P; Santaquilani M; Simonetti A; Tavilla A; Verdecchia A; Dalmas M; Langmark F; Bray F; Johannesen TB; Rachtan J; Góźdź S; Siudowska U; Mezyk R; Bielska-Lasota M; Zwierko M; Pinheiro PS; Primic-Zakelj M; Mateos A; Izarzugaza I; Torrella-Ramos A; Zurriaga O; Marcos-Gragera R; Vilardell ML; Izquierdo A; Martinez-Garcia C; Sánchez MJ; Navarro C; Chirlaque MD; Peris-Bonet R; Ardanaz E; Moreno C; Galceran J; Klint A; Talbäck M; Jundt G; Usel M; Frick H; Ess SM; Bordoni A; Luthi JC; Konzelmann I; Probst N; Lutz JM; Pury P; Visser O; Otter R; Schaapveld M; Coebergh JW; Janssen-Heijnen ML; van der Heijden L; Greenberg DC; Coleman MP; Woods L; Moran T; Forman D; Cooper N; Roche M; Verne J; Møller H; Meechan D; Poole J; Lawrence G; Stiller C; Gavin A; Black RJ; Brewster DH; Steward JA
  •  go-up   go-down


63. Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G, Kaltenbach S, Yakouben K, Mazingue F, Robert A, Boutard P, Plantaz D, Rohrlich P, van Vlierberghe P, Preudhomme C, Otten J, Speleman F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Cavé H, EORTC-CLG: NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia; 2010 Dec;24(12):2023-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.
  • Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy.
  • Although clinical presentations were not significantly associated with NOTCH status, NOTCH+ patients showed a better early response to chemotherapy as compared with NOTCH- patients, according to the rate of poor pre-phase 'responders' (25% versus 44%; P=0.02) and the incidence of high minimal residual disease (MRD) levels (11% (7/62) versus 32% (10/31); P=0.01) at completion of induction.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Child. Disease-Free Survival. Humans. Prospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2010 Dec;24(12):2003-4 [21157484.001]
  • (PMID = 20861920.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-20; United States / NCI NIH HHS / CA / 5U10 CA11488-21; United States / NCI NIH HHS / CA / 5U10 CA11488-22; United States / NCI NIH HHS / CA / 5U10 CA11488-23; United States / NCI NIH HHS / CA / 5U10 CA11488-24; United States / NCI NIH HHS / CA / 5U10 CA11488-25; United States / NCI NIH HHS / CA / 5U10 CA11488-26; United States / NCI NIH HHS / CA / 5U10 CA11488-27; United States / NCI NIH HHS / CA / 5U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-30; United States / NCI NIH HHS / CA / 5U10 CA11488-31; United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34; United States / NCI NIH HHS / CA / 5U10 CA11488-35; United States / NCI NIH HHS / CA / 5U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-37; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10 CA11488-39
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


64. Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, Dörken B, Arnold R: A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica; 2010 May;95(5):810-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.
  • BACKGROUND: Disease stage is the most important prognostic parameter in allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia, but other factors such as donor/host histocompatibility and gender combination, recipient age, performance status and comorbidities need to be considered.
  • Several scoring systems are available to predict outcome in HCT recipients; however, their prognostic relevance in acute lymphoblastic leukemia is not well defined.
  • DESIGN AND METHODS: In the present study we evaluated a modified EBMT risk score (mEBMT) and the HCT-specific comorbidity index (HCT-CI) in 151 adult acute lymphoblastic leukemia patients who received allogeneic HCT from 1995 until 2007 at our center.
  • RESULTS: Disease status was first complete remission (CR1) (47%), CR>1 (21%) or no CR (32%).
  • Disease stage was the predominant prognostic factor in this score.
  • Comorbidities were present in 71% of patients with mild hepatic disease (29%), moderate pulmonary disease (28%) and infections (23%) being the most common.
  • However, KPS was associated with disease stage and significance was lost in multivariate analysis.
  • CONCLUSIONS: The mEBMT was prognostic in our patient cohort with predominant influence of disease stage, whereas a trend but no significant prognostic value was observed for the HCT-CI.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / standards. Karnofsky Performance Status / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Preoperative Care / standards. Transplantation Conditioning / standards

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2003 Jul;9(7):472-81 [12869961.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Bone Marrow Transplant. 1996 Jan;17(1):13-8 [8673048.001]
  • [Cites] Lancet. 1998 Oct 3;352(9134):1087-92 [9798583.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):407-14 [16549853.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):201-9 [16939494.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41 [17640597.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):381-7 [17563735.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4246-54 [17724349.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507 [18022580.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4606-13 [17873123.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35 [18158958.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(8):721-7 [18176613.001]
  • [Cites] Cancer. 2008 May 1;112(9):1992-2001 [18311781.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):805-12 [18195682.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9):985-92 [18721761.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5585-93 [18765552.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25 [18940675.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):395-403 [18759762.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2062-9 [18685612.001]
  • [Cites] Eur J Clin Invest. 2008 Dec;38(12):945-52 [19021720.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):149-53 [19147097.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):223-30 [19167682.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(2):133-9 [18762762.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1131-8 [19194465.001]
  • [Cites] Curr Hematol Malig Rep. 2009 Jul;4(3):139-47 [20425427.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1596-9 [12886248.001]
  • (PMID = 20007143.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864388
  •  go-up   go-down


65. Yadav SP, Kalra M, Anjan M, Sachdeva A: Survival outcome in childhood acute lymphoblastic leukemia in India. Pediatr Blood Cancer; 2010 Jan;54(1):178; author reply 179
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcome in childhood acute lymphoblastic leukemia in India.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


66. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell; 2005 Feb;7(2):129-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / chemistry. Pyrimidines / pharmacology
  • [MeSH-minor] Animals. Benzamides. Bone Marrow Cells / cytology. Cell Line. Cell Line, Tumor. Cell Survival. Crystallography, X-Ray. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Hematopoietic Stem Cells / cytology. Imatinib Mesylate. Inhibitory Concentration 50. Mice. Models, Biological. Models, Chemical. Mutation. Mycoplasma / metabolism. Phosphorylation. Piperazines / pharmacology. Retroviridae / genetics. Time Factors

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Cell. 2005 Apr;7(4):399. Mohammed, Azam [corrected to Azam, Mohammad]
  • (PMID = 15710326.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA36167; United States / NCI NIH HHS / CA / CA66996; United States / NCI NIH HHS / CA / CA86991; United States / NIDDK NIH HHS / DK / DK50654
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


67. Tsimberidou AM, Keating MJ: Richter's transformation in chronic lymphocytic leukemia. Semin Oncol; 2006 Apr;33(2):250-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Richter's transformation in chronic lymphocytic leukemia.
  • Richter's syndrome (RS) is characterized by the development of high-grade non-Hodgkin's lymphoma (NHL) in a patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
  • The therapeutic strategies for RS typically include therapies developed for NHL or acute lymphoblastic leukemia.
  • Patients appear to benefit from cytoreductive therapy consisting of chemotherapy and immunotherapy, followed by allogeneic stem cell transplantation, as postremission therapy.
  • As part of a program aiming to cure RS, we are currently conducting a clinical trial of oxaliplatin, fludarabine, and cytarabine in combination with rituximab and recommend postremission therapy, including allogeneic stem cell transplantation in patients with available donors.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Non-Hodgkin. Neoplasms, Multiple Primary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cell Transformation, Neoplastic / pathology. Humans. Prognosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616072.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 78
  •  go-up   go-down


68. Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S, Kasahara S, Sato A, Monma F, Nagamura F, Iseki T, Tojo A, Asano S: Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL. Bone Marrow Transplant; 2009 Mar;43(6):455-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the disease-specific outcomes of adult ALL treated with cord blood transplantation (CBT) after myeloablative conditioning.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Fetal Blood / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease. Humans. Incidence. Male. Middle Aged. Recurrence. Retrospective Studies. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955981.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR: Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A; 2009 Aug 4;106(31):12944-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia.
  • Pediatric de novo acute myeloid leukemia (AML) is an aggressive malignancy with current therapy resulting in cure rates of only 60%.
  • To approach this goal, we examined diagnostic leukemic samples from a cohort of 111 children with de novo AML using single-nucleotide-polymorphism microarrays and candidate gene resequencing.
  • Our data demonstrate that, in contrast to pediatric acute lymphoblastic leukemia (ALL), de novo AML is characterized by a very low burden of genomic alterations, with a mean of only 2.38 somatic copy-number alterations per leukemia, and less than 1 nonsynonymous point mutation per leukemia in the 25 genes analyzed.
  • Even more surprising was the observation that 34% of the leukemias lacked any identifiable copy-number alterations, and 28% of the leukemias with recurrent translocations lacked any identifiable sequence or numerical abnormalities.
  • The only exception to the presence of few mutations was acute megakaryocytic leukemias, with the majority of these leukemias being characterized by a high number of copy-number alterations but rare point mutations.
  • These data reflect a remarkably low burden of genomic alterations within pediatric de novo AML, which is in stark contrast to most other human malignancies.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2008 Apr 2;640(1-2):97-106 [18243251.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1534-42 [17954704.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):729-39 [18506749.001]
  • [Cites] Leuk Lymphoma. 2008 Jun;49(6):1178-83 [18452069.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9 [18852474.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10349-57 [19074904.001]
  • [Cites] Nature. 2009 Mar 12;458(7235):223-7 [19182780.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):157-63 [17133407.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4903-10 [15077163.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6612-20 [15208665.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1831-4 [15385933.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2121-30 [8950979.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1361-6 [15902284.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2101-16 [16136167.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Blood. 2006 May 15;107(10):3847-53 [16434492.001]
  • [Cites] PLoS Comput Biol. 2006 May;2(5):e41 [16699594.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3735-44 [16449964.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3887-94 [16864856.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1282-97 [16893685.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Curr Oncol Rep. 2006 Nov;8(6):430-6 [17040621.001]
  • [Cites] Am J Hum Genet. 2007 Nov;81(5):906-12 [17924334.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jan;324(1):86-94 [17959747.001]
  • [Cites] Br J Haematol. 2008 Jan;140(2):123-32 [18173751.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • (PMID = 19651601.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCDC26 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / MLLT4 protein, human; 0 / Proto-Oncogene Proteins; 0 / RUNX1T1 protein, human; 0 / Transcription Factors; EC 3.6.1.- / Kinesin; EC 3.6.4.1 / Myosins
  • [Other-IDs] NLM/ PMC2716382
  •  go-up   go-down


70. Lowas S, Malempati S, Marks D: Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Jul;53(1):58-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Pediatric acute lymphoblastic leukemia (ALL) therapies have been associated with many late effects, including obesity, hyperglycemia, and insulin resistance.
  • Mean (+/-SD) diagnosis age 5.7 +/- 3.5 years, mean study age 11.3 +/- 3.7 years, mean time off therapy 2.8 +/- 1.5 years.
  • Waist/hip ratio and BMI at ALL diagnosis also correlated with insulin resistance, but these factors' effects could not be separated from BMI at study time.
  • [MeSH-major] Body Mass Index. Hyperglycemia / epidemiology. Insulin Resistance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Survivors / statistics & numerical data

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] Drug Saf. 1996 Aug;15(2):135-57 [8884164.001]
  • [Cites] Diabetes Care. 1999 Sep;22(9):1462-70 [10480510.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Nov;28 Suppl 3:S70-4 [15543223.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] Pediatrics. 2005 Aug;116(2):473-80 [16061606.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Sep;34(3):659-76, ix-x [16085165.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Sep;27(9):499-501 [16189445.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):960-3 [15700246.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] Haematologica. 2006 Oct;91(10):1424-5 [16963397.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Apr-May;17(3):231-7 [10779989.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):165-72 [11836715.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1728-32 [12365956.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):127-8 [14726167.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39 [15181020.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5003-12 [15472198.001]
  • [Cites] Am J Med Sci. 1976 Mar-Apr;271(2):202-10 [178180.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Pediatr Res. 1989 Aug;26(2):158-61 [2671905.001]
  • [Cites] Horm Res. 1991;35(3-4):155-60 [1725285.001]
  • [Cites] J Med. 1994;25(3-4):219-29 [7996065.001]
  • [Cites] J Pediatr. 1995 Jul;127(1):63-7 [7608813.001]
  • [Cites] Pediatr Res. 1995 Jul;38(1):86-90 [7478803.001]
  • (PMID = 19340854.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024140; United States / NCRR NIH HHS / RR / UL1 RR024140; United States / NCRR NIH HHS / RR / UL1 RR024140-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS123017; NLM/ PMC3804011
  •  go-up   go-down


71. Li Q, Chen Z, You Y, Zou P: Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome. Leuk Res; 2008 Aug;32(8):1317-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome.
  • Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL) is a rare but well-known occurrence usually affecting children and adolescents.
  • To the best of our knowledge, this is the first report of adult B-cell type pre-ALL with positive Philadelphia chromosome and P190(BCR-ABL) published in the literature.
  • We report the case of a 49-year-old woman who was diagnosed with B-cell type ALL associated positive Philadelphia chromosome and P190(BCR-ABL) preceded by transient pancytopenia.
  • The clinical, morphologic, immunophenotypic and molecular features of this patient are described and the literature reviewed.
  • [MeSH-major] Pancytopenia / diagnosis
  • [MeSH-minor] Female. Fusion Proteins, bcr-abl / analysis. Humans. Immunophenotyping. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Preleukemia / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291524.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


72. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood; 2007 Apr 15;109(8):3214-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
  • Central nervous system (CNS) prophylaxis has led to a significant improvement in the outcome of patients with acute lymphocytic leukemia (ALL).
  • Liposomal cytarabine 50 mg was given intrathecally on days 2 and 15 of hyper-CVAD and day 10 of high-dose MTX and cytarabine courses until completion of either 3, 6, or 10 IT treatments, depending on risk for CNS disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemic Infiltration / prevention & control. Meninges. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2007 Sep 1;110(5):1698; author reply 1698-9 [17712051.001]
  • (PMID = 17209054.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


73. Pan JL, Xue YQ, Jiang HY, Zhu YJ, Ma L, Li TY, Wang Y, Wu YF: [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)].
  • OBJECTIVE: To investigate the laboratory and clinical features of 7 cases of acute lymphoblastic leukemia (ALL) with dic(7;9) (pll;pll).
  • RESULTS: Seven (0.88%) of 800 ALL patients were found to have dic(7;9) abnormality.
  • Among them, dic(7;9) was the sole abnormality in 2 cases, t(9;22), other additional aberrations besides dic(7;9) in 4 cases and dic (7;9) with other abnormalities but no t(9;22) in one case.
  • CONCLUSION: dic(7;9) was a rare, but recurrent chromosome abnormality in ALL and had some clinical and laboratory features.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383241.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


74. Pottier N, Yang W, Assem M, Panetta JC, Pei D, Paugh SW, Cheng C, Den Boer ML, Relling MV, Pieters R, Evans WE, Cheok MH: The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst; 2008 Dec 17;100(24):1792-803
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
  • BACKGROUND: Glucocorticoids are used in the curative treatment of acute lymphoblastic leukemia (ALL).
  • Prednisolone resistance was higher in SMARCA4 shRNA-transfected Jurkat cells (drug concentration lethal to 50% of the leukemia cells [LC(50)] = 277 microM) than in control shRNA-transfected cells (LC(50) = 174 microM, difference = 103 microM, 95% confidence interval of the difference = 100 to 106 microM; P < .001, t test).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Glucocorticoid Resistance.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 2005 May-Jun;70(5-7):407-17 [15862824.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2519-26 [15572593.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1817-23 [15899912.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1279-81 [16154856.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9712-8 [16266991.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Dec;14(12):1527-45 [16307492.001]
  • [Cites] Mol Endocrinol. 2006 Jan;20(1):1-13 [16002433.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):164-73 [16388947.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2004-13 [10688647.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2056-62 [10766198.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2234-9 [11187914.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3365-74 [11694573.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1437-42 [12145682.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):41674-85 [12200431.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] Curr Opin Genet Dev. 2003 Apr;13(2):136-42 [12672490.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6210-20 [12917342.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4541-6 [12920041.001]
  • [Cites] Curr Opin Cell Biol. 2006 Jun;18(3):267-74 [16574391.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1045-9 [16574952.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1984-90 [16709928.001]
  • [Cites] Genes Dev. 2006 Oct 15;20(20):2871-86 [17043312.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:162-7 [17240047.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):93-9 [14693814.001]
  • [Cites] Hum Mol Genet. 2007 Oct 1;16(19):2261-71 [17616514.001]
  • [Cites] Leukemia. 2004 Mar;18(3):530-7 [14724649.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3347-58 [15060156.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43708-15 [15292225.001]
  • [Cites] Cancer Res. 1985 Dec;45(12 Pt 1):6482-6 [3864532.001]
  • [Cites] EMBO J. 1987 Aug;6(8):2321-8 [2822386.001]
  • [Cites] Mol Cell Biol. 1991 Feb;11(2):688-98 [1846670.001]
  • [Cites] Lancet. 1991 Aug 17;338(8764):399-403 [1678081.001]
  • [Cites] Science. 1992 Dec 4;258(5088):1598-604 [1360703.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):849-52 [8479523.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4059-65 [8358735.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):348-53 [7812967.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):663-8 [8938150.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):895-905 [9001244.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2959-65 [9108416.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Nature. 1998 May 7;393(6680):88-91 [9590696.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Curr Biol. 1999 Mar 25;9(6):R221-4 [10209086.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3505-9 [15755863.001]
  • (PMID = 19066270.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Chromosomal Proteins, Non-Histone; 0 / Glucocorticoids; 0 / Nuclear Proteins; 0 / SWI-SNF-B chromatin-remodeling complex; 0 / Transcription Factors; 9PHQ9Y1OLM / Prednisolone; EC 3.6.1.- / SMARCA4 protein, human; EC 3.6.4.- / DNA Helicases
  • [Other-IDs] NLM/ PMC2639326
  •  go-up   go-down


75. Shonubi AM, Odusan O, Oloruntoba DO, Agbahowe SA, Siddique MA: "Health for all" in a least-developed country. J Natl Med Assoc; 2005 Jul;97(7):1020-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Health for all" in a least-developed country.
  • The World Health Organization's (WHO) concept of primary healthcare as the basis for comprehensive healthcare delivery for developing countries has not been effectively applied in many of these countries.
  • The Kingdom of Lesotho, one of the world's least-developed countries, has been able to provide a fairly comprehensive healthcare system for its citizenry based on prmary healthcare principles and a strong commitment on the part of the government despite severe limitations of finance and human resource capacity as well as difficult mountainous terrains.
  • This paper presents the highlights of this system of healthcare delivery with the hope that other developing countries would draw some lessons from the model.
  • [MeSH-major] Comprehensive Health Care / organization & administration. Delivery of Health Care / organization & administration. Developing Countries. Health Promotion
  • [MeSH-minor] Health Expenditures / statistics & numerical data. Health Services Accessibility. Hospitals, District. Humans. Lesotho. Public Health Administration. Regional Health Planning. World Health Organization

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bull World Health Organ. 2000;78(6):761-9 [10916913.001]
  • [Cites] Instr Course Lect. 2000;49:567-73 [10829211.001]
  • [Cites] Annu Rev Public Health. 1990;11:335-58 [2191665.001]
  • [Cites] J Am Acad Orthop Surg. 2001 Sep-Oct;9(5):289-96 [11575908.001]
  • [Cites] J Bone Joint Surg Br. 1985 Nov;67(5):840-2 [4055888.001]
  • [Cites] Instr Course Lect. 2000;49:579-83 [10829213.001]
  • (PMID = 16080673.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569324
  •  go-up   go-down


76. Yoshimura I, Naito M, Kanazawa K, Takeyama A, Karashima H, Ida T, Nomura T: Arthroscopic treatment for an osteochondral defect of the talus after necrosis associated with acute lymphoblastic leukaemia: a case report. Foot Ankle Surg; 2010 Dec;16(4):e88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arthroscopic treatment for an osteochondral defect of the talus after necrosis associated with acute lymphoblastic leukaemia: a case report.
  • Osteonecrosis is a serious complication of acute lymphoblastic leukemia (ALL) therapy.
  • [MeSH-minor] Adrenal Cortex Hormones / adverse effects. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow / physiology. Female. Humans. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Wound Healing

  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 21047598.001).
  • [ISSN] 1460-9584
  • [Journal-full-title] Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  • [ISO-abbreviation] Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


77. Bacher U, Kohlmann A, Haferlach T: Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol; 2009 Jun;145(5):555-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
  • Gene expression profiling (GEP) enables the simultaneous investigation of the expression of tens of thousands of genes and was successfully introduced in leukaemia research a decade ago.
  • Aiming to better understand the diversity of genetic aberrations in acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), pioneer studies investigated and confirmed the predictability of many cytogenetic and molecular subclasses in AML and ALL.
  • In addition, GEP can define new prognostic subclasses within distinct leukaemia subgroups, as illustrated in AML with normal karyotype.
  • Another approach is the development of treatment-specific sensitivity assays, which might contribute to targeted therapy studies.
  • Finally, GEP might enable the detection of new molecular targets for therapy in patients with acute leukaemia.
  • Meanwhile, large multicentre studies, e.g. the Microarray Innovations in LEukaemia (MILE) study, prepare for a standardised introduction of GEP in leukaemia diagnostic algorithms, aiming to translate this novel methodology into clinical routine for the benefit of patients with the complex disorders of AML and ALL.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Gene Expression. Gene Rearrangement. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344393.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 118
  •  go-up   go-down


78. Hamamoto K, Oriuchi N, Kanazawa T, Higuchi T, Endo K: Mesial temporal sclerosis associated with methotrexate-induced leukoencephalopathy. Pediatr Neurol; 2009 Apr;40(4):306-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesial temporal sclerosis is a common form of symptomatic, localization-related epilepsy in children and adolescents, but its occurrence with acute lymphoblastic leukemia is rare.
  • We present clinical records and neuroimaging results of a 13-year-old patient with acute lymphoblastic leukemia who developed recurrent partial seizures after an episode of leukoencephalopathy thought to be caused by methotrexate.
  • Mesial temporal sclerosis was not previously reported in acute lymphoblastic leukemia patients with methotrexate-induced leukoencephalopathy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Positron-Emission Tomography. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sclerosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302946.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Malempati S, Tibbitts D, Cunningham M, Akkari Y, Olson S, Fan G, Sears RC: Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia; 2006 Sep;20(9):1572-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias.
  • Overexpression of the c-Myc oncoprotein is observed in a large number of hematopoietic malignancies, and transgenic animal models have revealed a potent role for c-Myc in the generation of leukemias and lymphomas.
  • We examined whether aberrant protein stabilization could be a mechanism of c-Myc overexpression in leukemia cell lines and in primary bone marrow samples from pediatric acute lymphoblastic leukemia (ALL) patients.
  • We found that c-Myc protein half-life was prolonged in the majority of leukemia cell lines and bone marrow samples tested.
  • There were no mutations in the c-myc gene in any of the leukemia cell lines that could account for increased c-Myc stability.
  • However, abnormal phosphorylation at two conserved sites, Threonine 58 and Serine 62, was observed in leukemia cell lines with stabilized c-Myc.
  • Moreover, stabilized c-Myc from the ALL cell lines showed decreased affinity for glycogen synthase kinase3beta, the kinase that phosphorylates c-Myc at Threonine 58 and facilitates its degradation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32475-81 [10913153.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2275-84 [12399973.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25802-7 [12734207.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1833-41 [12714522.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51606-12 [14563837.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]
  • [Cites] EMBO J. 2004 May 19;23(10):2116-25 [15103331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90 [15150404.001]
  • [Cites] Nature. 1982 Sep 2;299(5878):61-3 [6955596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nature. 1983 Aug 18-24;304(5927):596-602 [6308472.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):603-10 [6606489.001]
  • [Cites] Blood. 1984 Dec;64(6):1234-9 [6208953.001]
  • [Cites] Mol Cell Biol. 1984 Nov;4(11):2486-97 [6513926.001]
  • [Cites] Nature. 1986 Aug 28-Sep 3;322(6082):848-50 [3528863.001]
  • [Cites] Annu Rev Genet. 1986;20:361-84 [3028245.001]
  • [Cites] Mol Cell Biol. 1987 Dec;7(12):4513-21 [3325826.001]
  • [Cites] Curr Top Microbiol Immunol. 1988;141:82-93 [3215058.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):3952-64 [2196440.001]
  • [Cites] Genes Dev. 1990 Dec;4(12A):2025-35 [2269425.001]
  • [Cites] Oncogene. 1991 May;6(5):797-805 [2052358.001]
  • [Cites] Genes Dev. 1993 Apr;7(4):671-82 [8458579.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3383-6 [8012955.001]
  • [Cites] Mol Cell Biol. 1994 Aug;14(8):5510-22 [8035827.001]
  • [Cites] Blood. 1994 Aug 1;84(3):883-8 [8043869.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2439-44 [8570196.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5513-8 [8621409.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5961-9 [9742113.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):717-26 [9927431.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):185-93 [9931326.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):169-79 [10078200.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8571-80 [15467756.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1133-7 [15467447.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2423-35 [10713166.001]
  • (PMID = 16855632.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100855-02; United States / NCI NIH HHS / CA / CA086957-05; United States / NCI NIH HHS / CA / R01 CA100855; United States / NCI NIH HHS / CA / CA100855-02; United States / NCI NIH HHS / CA / K01 CA086957; United States / NCI NIH HHS / CA / K01 CA086957-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 3.4.99.- / ATP dependent 26S protease
  • [Other-IDs] NLM/ NIHMS42996; NLM/ PMC2322939
  •  go-up   go-down


80. Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G: A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf; 2008 Aug;17(8):769-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
  • PURPOSE: Retrospectively investigate potential associations between rosiglitazone and congestive heart failure (CHF) and, separately, events of myocardial ischemia.
  • METHODS: Data from 14 237 individuals in 42 short-term, double-blind, randomized studies of rosiglitazone versus placebo or active diabetes medications were analyzed across seven treatment comparisons using an exact logistic regression model, adjusted for number of major cardiovascular risk factors and duration of exposure.
  • RESULTS: CHF incidence ranged 0-1.27% (SAEs) and 0.12-2.42% (all AEs) with rosiglitazone versus 0.07-0.75% (SAEs) and 0.25-1.36% (all AEs) with control.
  • Higher odds ratios (95%CI) were observed for CHF SAEs with sulfonylurea- and insulin-containing combinations: rosiglitazone monotherapy versus placebo, 0.25 (<0.01-4.75); rosiglitazone monotherapy versus sulfonylurea/metformin monotherapy, 0.23 (<0.01-2.14); sulfonylurea + rosiglitazone versus sulfonylurea monotherapy, 0.95 (0.01-75.20); metformin + rosiglitazone versus metformin monotherapy, 0.60 (0.00-8.28); metformin + rosiglitazone versus metformin + sulfonylurea, 1.04 (0.39-2.86); sulfonylurea + metformin + rosiglitazone versus sulfonylurea + metformin, 3.15 (0.35-150.52); insulin + rosiglitazone versus insulin monotherapy, 1.63 (0.52-6.01).
  • Myocardial ischemia incidence ranged 0.75-1.40% (SAEs) and 1.49-2.77% (all AEs) with rosiglitazone versus 0.21-2.04% (SAEs) and 0.56-2.38% (all AEs) with control.
  • Each comparison had an OR >1, with wide confidence intervals generally including unity.
  • With data pooling, more events of myocardial ischemia were observed with rosiglitazone (2.00%) versus control (1.53%) (HR 1.30, 95%CI 1.004-1.69).
  • CONCLUSIONS: CHF incidence may be greater when rosiglitazone is combined with sulfonylureas or insulin.
  • When data were pooled, more events of myocardial ischemia were observed with rosiglitazone versus control.
  • Final results from RECORD will allow a more rigorous evaluation of the cardiovascular safety profile.
  • [MeSH-major] Diabetes Mellitus, Type 2 / complications. Heart Failure / chemically induced. Hypoglycemic Agents / adverse effects. Myocardial Ischemia / chemically induced. Thiazolidinediones / adverse effects
  • [MeSH-minor] Aged. Double-Blind Method. Female. Humans. Male. Middle Aged. Odds Ratio. Randomized Controlled Trials as Topic. Retrospective Studies. Time Factors


81. Kyonen L M, Folatre B I, Zolezzi R P, Badilla M V, Marín H F: [Adverse reactions to L-asparaginase in children with acute lymphatic leukemia]. Rev Med Chil; 2006 Dec;134(12):1530-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adverse reactions to L-asparaginase in children with acute lymphatic leukemia].
  • [Transliterated title] Reacciones adversas a L-asparaginasa en pacientes con leucemia linfoblástica aguda.
  • AIM: To communicate the ADR observed with the use E coli asparaginase (E coli ASP) in children with Acute Lymphatic Leukemia (ALL).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277869.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


82. Ansari M, St-Onge G, Krajinovic M: [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris); 2007 Nov;23(11):961-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacogenomics of acute lymphoblastic leukemia].
  • [Transliterated title] Pharmacogénétique de la leucémie lymphoblastique aiguë
  • Pharmacogenomics of acute lymphoblastic leukemia (ALL) evolved rapidly in the past few years.
  • Leukemia is the most common cancer affecting children, with ALL comprising 80 % of all leukemia cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021708.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


83. Naunheim MR, Nahed BV, Walcott BP, Kahle KT, Soupir CP, Cahill DP, Borges LF: Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. Clin Neurol Neurosurg; 2010 Sep;112(7):575-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature.
  • Intracerebral hemorrhage (ICH) contributes significantly to the morbidity and mortality of patients suffering from acute leukemia.
  • While ICH is often identified in autopsy studies of leukemic patients, it is rare for ICH to be the presenting sign that ultimately leads to the diagnosis of leukemia.
  • We report a patient with previously undiagnosed acute precursor B-cell lymphoblastic leukemia (ALL) who presented with diffuse encephalopathy due to ICH in the setting of an acute blast crisis.
  • The diagnosis of ALL was initially suspected, because of the hyperleukocytosis observed on presentation, then confirmed with a bone marrow biopsy and flow cytometry study of the peripheral blood.
  • This case demonstrates that the presence of hyperleukocytosis in a patient with intracerebral hemorrhage should raise clinical suspicion for acute leukemia as the cause of the ICH.
  • [MeSH-major] Blast Crisis / diagnosis. Intracranial Hemorrhages / diagnosis. Leukemia, Biphenotypic, Acute / diagnosis
  • [MeSH-minor] Benzamides. Blood Cell Count. Diagnosis, Differential. Flow Cytometry. Humans. Imatinib Mesylate. In Situ Hybridization. Leukocyte Count. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20493628.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


84. Grüllich C, Friske V, Finke J: Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death. Ann Hematol; 2008 Sep;87(9):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death.
  • Cytotoxic T lymphocytes and natural killer cells (CTL/NK) induce cell death in leukemia cells by the granzyme B (grB)-dependent granule cytotoxin (GC) pathway.
  • Resistance to GC may be involved in immune evasion of leukemia cells.
  • We developed a rapid method for the isolation of GC to investigate GC-mediated cell death in primary leukemia cells.
  • We isolated GC containing grB, grB complexes and PFN by detergent free hypotonic lysis of the human NK cell leukemia line YT.
  • The human leukemia cell lines KG-1, U937, K562 (myeloid leukemia), Jurkat, Daudi, and BV173 (lymphoblastic leukemia) treated with GC internalized grB and underwent cell death.
  • In primary leukemia cells analyzed ex vivo, we found GC-resistant leukemia cells in three out of seven patients with acute myeloid leukemia and one out of six patients with acute lymphoblastic leukemia.
  • We conclude that our method is fast (approximately 1 h) and yields active GC that induce grB-dependent cell death.
  • Furthermore, resistance to GC can be observed in acute leukemias and may be an important mechanism contributing to leukemia cell immune evasion.
  • [MeSH-major] Cell Death / drug effects. Cytotoxins / toxicity. Granzymes / toxicity. Leukemia / pathology
  • [MeSH-minor] Cell Line, Tumor. Drug Resistance, Neoplasm. Humans. K562 Cells / drug effects. K562 Cells / pathology. Killer Cells, Natural / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Myeloid, Acute / pathology. Perforin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. T-Lymphocytes, Cytotoxic / immunology. U937 Cells / drug effects. U937 Cells / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437383.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytotoxins; 126465-35-8 / Perforin; EC 3.4.21.- / Granzymes
  •  go-up   go-down


85. Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE, Haffner SM: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation; 2005 Dec 13;112(24):3713-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In addition to predicting cardiovascular disease (CVD) morbidity and mortality, the metabolic syndrome is strongly associated with the development of type 2 diabetes mellitus (DM), itself an important risk factor for CVD.
  • [MeSH-major] Diabetes Mellitus, Type 2 / diagnosis. Metabolic Syndrome X / classification. Metabolic Syndrome X / complications

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • Genetic Alliance. consumer health - Diabetes mellitus type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Circulation. 2005 Dec 13;112(24):3675-6 [16344398.001]
  • (PMID = 16344402.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-29867; United States / NCRR NIH HHS / RR / M01-RR-43; United States / PHS HHS / / R01 58329; United States / NHLBI NIH HHS / HL / U01-HL47887; United States / NHLBI NIH HHS / HL / U01-HL47889; United States / NHLBI NIH HHS / HL / U01-HL47892; United States / NHLBI NIH HHS / HL / U01-HL47902
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Zecca G, Gradi EC, Nilsson K, Bellotti M, Dal Verme S, Vegni E, Moja EA: "All the rest is normal". A pilot study on the communication between physician and patient in prenatal diagnosis. J Psychosom Obstet Gynaecol; 2006 Sep;27(3):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "All the rest is normal". A pilot study on the communication between physician and patient in prenatal diagnosis.
  • The aim of the study was to verify in the context of prenatal diagnosis if the communicative style in consultations is modified in relation to the seriousness of the diagnosis.
  • The communication during the consultation seems to be mostly influenced by a highly disease-centered model that is not dependent on the content of the consultation itself.
  • Only emotional exchanges showed a marginally significant decrease in the H visits (t = 1.995, p = 0.057), suggesting the probable difficulty of the disease-centered model to manage emotional items during a highly dramatic consultation.
  • [MeSH-major] Communication. Fetal Diseases / diagnosis. Fetal Diseases / psychology. Physician-Patient Relations. Prenatal Diagnosis / psychology


87. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK: Body composition in children in remission from acute lymphoblastic leukemia. Am J Clin Nutr; 2006 Jan;83(1):70-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in children in remission from acute lymphoblastic leukemia.
  • BACKGROUND: Changes in body composition are commonly reported in pediatric survivors of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Adipose Tissue / metabolism. Body Composition. Body Water / metabolism. Muscle, Skeletal / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. DEUTERIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400052.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; AR09D82C7G / Deuterium
  •  go-up   go-down


88. Arhan E, Kaya Z, Serdaroğlu A, Ozcelik AA, Bilir E, Durdağ E, Kurt G, Albayrak M: Successful surgical treatment of medically refractory epilepsy after chemotherapy in a child with leukemia: a case report. Neurologist; 2010 Jan;16(1):41-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful surgical treatment of medically refractory epilepsy after chemotherapy in a child with leukemia: a case report.
  • INTRODUCTION: Mesial temporal sclerosis associated with acute lymphoblastic leukemia has been rarely reported.
  • CASE REPORT: We report a case of a 15-year-old boy with acute lymphoblastic leukemia who developed medically refractory temporal lobe epilepsy in a long time period after chemotherapy, and successfully treated with surgical resection.
  • [MeSH-major] Epilepsy / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065796.001).
  • [ISSN] 2331-2637
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents
  •  go-up   go-down


89. Archangelo LF, Gläsner J, Krause A, Bohlander SK: The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene; 2006 Jul 6;25(29):4099-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM or PICALM) was first identified as the fusion partner of AF10 in the t(10;11)(p13;q14) translocation, which is observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and malignant lymphoma.
  • The interaction between CALM and CATS could be confirmed using pull down assays, co-immunoprecipitation and colocalization experiments.
  • [MeSH-major] Active Transport, Cell Nucleus. Carrier Proteins / metabolism. Cell Nucleolus / metabolism. Monomeric Clathrin Assembly Proteins / metabolism. Oncogene Proteins, Fusion / metabolism
  • [MeSH-minor] 3T3 Cells. Animals. Base Sequence. Cell Transformation, Neoplastic / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 10 / metabolism. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 13 / metabolism. Gene Expression Regulation / genetics. Humans. Mice. Molecular Sequence Data. Organ Specificity. Protein Binding / genetics. Translocation, Genetic / genetics

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491119.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Carrier Proteins; 0 / FAM64A protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human
  •  go-up   go-down


90. Yang HK, Yu HG: Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease. Korean J Ophthalmol; 2009 Dec;23(4):325-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease.
  • We describe a case of bilateral exudative retinal detachment associated with prodromal symptoms simulating the presentation of acute Vogt-Koyanagi-Harada disease that was eventually diagnosed as acute lymphoblastic leukemia.
  • A clinical diagnosis of incomplete type Vogt-Koyanagi-Harada disease was considered.
  • However, complete blood cell count showed a marked increase in the number of white blood cells and bone marrow examination revealed precursor B cell lymphoblastic leukemia.
  • Bilateral exudative retinal detachment associated with neurologic and auditory abnormalities may be a presenting sign of acute lymphoblastic leukemia.
  • Clinicians should be aware of the possibility of leukemia in such patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology. Uveomeningoencephalitic Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Mar;17(3):150-5 [11486647.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):557-9 [12648516.001]
  • [Cites] Am J Ophthalmol. 1979 May;87(5):698-702 [443342.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Am J Ophthalmol. 1987 Oct 15;104(4):364-72 [3661646.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Am J Ophthalmol. 1990 Apr 15;109(4):436-44 [2330946.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):58-66 [8659599.001]
  • [Cites] Surv Ophthalmol. 1964 Oct;9:467-73 [14199728.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Am J Ophthalmol. 2007 Aug;144(2):260-5 [17533104.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Retina. 2003 Dec;23(6):820-46; quiz 895-6 [14707834.001]
  • [Cites] Acta Haematol. 2000;104(1):46-9 [11111123.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):647-52 [11336942.001]
  • [Cites] Retina. 2001;21(3):237-42 [11421013.001]
  • (PMID = 20046700.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789964
  • [Keywords] NOTNLM ; Exudative retinal detachment / Leukemia / Vogt-Koyanagi-Harada disease
  •  go-up   go-down


91. Beverland D: Patient satisfaction following TKA: Bless them all! Orthopedics; 2010 Sep;33(9):657
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient satisfaction following TKA: Bless them all!
  • Survivorship following modern total knee arthroplasty (TKA) is good with revision rates generally lower than for total hip arthroplasty (THA).
  • Our experience in Belfast supports that fact with original component survivorship of 99% for the low contact stress rotating platform TKA, which is better than our THA survivorship.
  • It is important to discriminate between survivorship and patient satisfaction.
  • In Belfast, as well as the more familiar outcome scores, we also use a very simple 4-point satisfaction questionnaire: "How would you best describe your satisfaction with your new joint" where 1=very happy, 2=happy, 3=OK but not perfect, and 4=I have never been happy.
  • We applied this questionnaire to our 10-year THA and TKA patients.
  • When we looked specifically at the numbers of patients who were either "very happy" or "never happy," the results were very different.
  • The very happy percentage for hips was much higher than for knees (54% vs 4%) and conversely, the number of never happy knees was much higher than for hips (7% vs 1%).
  • These results are not unique to Belfast.
  • As surgeons, we often think that the knee implant that we use is the best but at present, the implant is no longer the most critical factor.
  • We need to increase the number of very happy patients and decrease the number of never happy ones.
  • In my opinion the two key factors that we should focus on are patient expectation and surgeon education.
  • [MeSH-major] Arthroplasty, Replacement, Knee. Patient Satisfaction
  • [MeSH-minor] Arthroplasty, Replacement, Hip. Cohort Studies. Follow-Up Studies. Humans. Orthopedics / education. Patient Education as Topic. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 20839698.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Roy C: [Imaging of urinary lithiasis: "all in one"]. Ann Urol (Paris); 2006 Apr;40(2):69-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Imagerie de la lithiase urinaire: "Trois en un".
  • Helical CToperated with newer devices is the most accurate modality to provide all needed information: diagnosis of stone without contrast medium injection, morphology (size, number) and localization, diagnosis of urinary obstruction, urinary tract aspect and all kind of differential diagnosis in emergency.
  • Multiplanar reconstructions are essential for the clinicians; but diagnosis is interpreted by scrolling axial views with dynamic analysis on computer screen.
  • [MeSH-major] Urinary Calculi / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709006.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 69
  •  go-up   go-down


93. Meng CQ: Atherosclerosis is an inflammatory disorder after all. Curr Top Med Chem; 2006;6(2):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atherosclerosis is an inflammatory disorder after all.
  • Accumulating evidence has led to the conclusion that atherosclerosis is an inflammatory disease, although it was believed to be a disorder of high cholesterol levels in the bloodstream for over a century.
  • Statins lower cholesterol levels and hence reduce inflammation in the vasculature and prevent heart disease.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454761.001).
  • [ISSN] 1568-0266
  • [Journal-full-title] Current topics in medicinal chemistry
  • [ISO-abbreviation] Curr Top Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents
  • [Number-of-references] 89
  •  go-up   go-down


94. Nagano A, Komura T, Yoshioka S, Fukashiro S: Contribution of non-extensor muscles of the leg to maximal-effort countermovement jumping. Biomed Eng Online; 2005;4:52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of non-extensor muscles of the leg to maximal-effort countermovement jumping.
  • BACKGROUND: The purpose of this study was to determine the effects of non-extensor muscles of the leg (i.e., muscles whose primary function is not leg extension) on the kinematics and kinetics of human maximal-effort countermovement jumping.
  • Although it is difficult to address this type of question through experimental procedures, the methodology of computer simulation can be a powerful tool.
  • METHODS: A skeletal model that has nine rigid body segments and twenty degrees of freedom was developed.
  • Two sets of muscle models were attached to this skeletal model: all (most of) major muscles in the leg ("All Muscles" model) and major extensor muscles in the leg (i.e., muscles whose primary function is leg extension; "Extensors Only" model).
  • Neural activation input signal was represented by a series of step functions with a step duration of 0.05 s.
  • Simulations were started from an identical upright standing posture.
  • The optimal pattern of the activation input signal was searched through extensive random-search numerical optimization with a goal of maximizing the height reached by the mass centre of the body after jumping up.
  • RESULTS: The simulated kinematics was almost two-dimensional, suggesting the validity of two-dimensional analyses when evaluating net mechanical outputs around the joints using inverse dynamics.
  • A greater jumping height was obtained for the "All Muscles" model (0.386 m) than for the "Extensors Only" model (0.301 m).
  • For the "All Muscles" model, flexor muscles developed force in the beginning of the countermovement.
  • For the "All Muscles" model, the sum of the work outputs from non-extensor muscles was 47.0 J, which was 13% of the total amount (359.9 J).
  • The quantitative distribution of the work outputs from individual muscles was markedly different between these two models.
  • CONCLUSION: It was suggested that the contribution of non-extensor muscles in maximal-effort countermovement jumping is substantial.
  • The use of a computer simulation model that includes non-extensor muscles seems to be more desirable for the assessment of muscular outputs during jumping.
  • [MeSH-major] Joints / physiology. Leg / physiology. Movement / physiology. Muscle Contraction / physiology. Muscle, Skeletal / physiology. Physical Exertion / physiology. Postural Balance / physiology
  • [MeSH-minor] Computer Simulation. Humans. Models, Biological. Motor Skills / physiology. Physical Endurance / physiology. Task Performance and Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomech Eng. 1982 Nov;104(4):304-10 [7154650.001]
  • [Cites] J Biomech. 1990;23(1):91-5 [2307696.001]
  • [Cites] IEEE Trans Biomed Eng. 1990 Aug;37(8):757-67 [2210784.001]
  • [Cites] J Biomech. 1990;23(12):1185-98 [2292598.001]
  • [Cites] J Biomech. 1991;24(1):1-10 [2026629.001]
  • [Cites] J Biomech. 1993 Jan;26(1):1-8 [8423165.001]
  • [Cites] J Electromyogr Kinesiol. 2005 Aug;15(4):367-76 [15811607.001]
  • [Cites] Med Sci Sports Exerc. 1994 Aug;26(8):1012-20 [7968418.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1995;71(5):453-8 [8565978.001]
  • [Cites] J Biomech. 1996 Sep;29(9):1223-30 [8872282.001]
  • [Cites] Med Sci Sports Exerc. 1996 Nov;28(11):1402-12 [8933491.001]
  • [Cites] Exp Brain Res. 1998 Jul;121(1):76-91 [9698193.001]
  • [Cites] Am J Phys Anthropol. 2005 Jan;126(1):2-13 [15386246.001]
  • [Cites] J Biomech. 1993 Dec;26(12):1413-27 [8308046.001]
  • (PMID = 16143047.001).
  • [ISSN] 1475-925X
  • [Journal-full-title] Biomedical engineering online
  • [ISO-abbreviation] Biomed Eng Online
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215494
  •  go-up   go-down


95. Kager L: Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia. J BUON; 2009 Sep;14 Suppl 1:S181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is the classic example for a drug-responsive malignancy, and contemporary risk-directed therapies cure more than 80% of children with ALL in industrialized countries.
  • Moreover, some children have leukemia cell clones which are resistant to current antileukemic treatment.
  • As ALL is still among the leading causes of death from disease in children aged one to 15 years, further improvement of childhood ALL therapy is urgently needed.
  • [MeSH-major] Pharmacogenetics / methods. Precision Medicine / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


96. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J: Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood; 2010 Jul 1;115(26):5428-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Kinase Inhibitors / therapeutic use


97. Lancioni C, LaBeaud AD, Esper F, Abughali N, Auletta J: Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Dec 15;53(7):1318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia.
  • In this report we describe a case of primary pulmonary tuberculosis (TB) in a boy with precursor B-cell acute lymphoblastic leukemia (ALL) and review the pertinent literature.
  • [MeSH-major] Fever of Unknown Origin / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tuberculosis, Pulmonary / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. ISONIAZID .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • Hazardous Substances Data Bank. PYRAZINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19618457.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 04079A1RDZ / Cytarabine; 2KNI5N06TI / Pyrazinamide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 83905-01-5 / Azithromycin; 8G167061QZ / Ethambutol; 8N3DW7272P / Cyclophosphamide; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


98. Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol; 2008 Nov;143(4):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
  • The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) treated with imatinib-combined chemotherapy.
  • Of these, 10 of the 16 who had undergone allogeneic haematopoietic stem cell transplantation (HSCT) in first CR were alive without relapse at a median of 2.9 years after transplantation, whereas 12 of the 13 who had not undergone allogeneic HSCT experienced a relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fusion Proteins, bcr-abl / analysis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adolescent. Adult. Benzamides. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Piperazines / administration & dosage. Prognosis. Prospective Studies. Pyrimidines / administration & dosage. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Sep;146(5):576-7 [19555375.001]
  • (PMID = 18986386.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


99. Kager L, Evans WE: Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol; 2006 Jul;13(4):260-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries.
  • Pharmacogenomics, which studies the role of inheritance in individual variation in drug disposition and response, could be a useful tool to further improve outcome in this heterogeneous disease by individualization of therapy based on information gained from the genetic 'make-up' of normal host cells and lymphoblastic leukemia cells.
  • Thus there is great promise for advancing event-free survival in childhood leukemia in the future.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pharmacogenetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Disease-Free Survival. Humans. Randomized Controlled Trials as Topic. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755223.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


100. Mitchell C, Richards S, Harrison CJ, Eden T: Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia; 2010 Feb;24(2):406-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.
  • Between 1980 and 2001, the United Kingdom Medical Research Council Childhood Leukemia Working Party conducted four clinical trials in acute lymphoblastic leukaemia (ALL), which recruited a total of 6516 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Br J Haematol. 2009 Aug;146(4):424-36 [19549269.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):3-10 [11328273.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):445-55 [12139731.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1798-809 [12721257.001]
  • [Cites] J Clin Oncol. 1983 May;1(5):317-25 [6366138.001]
  • [Cites] Arch Dis Child. 1985 Nov;60(11):1050-4 [3907505.001]
  • [Cites] Lancet. 1986 Feb 22;1(8478):408-11 [2868339.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):189-90 [3462466.001]
  • [Cites] Arch Dis Child. 1987 Jan;62(1):12-8 [3468886.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):497-502 [2233523.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):187-96 [2064956.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):565-8 [1355153.001]
  • [Cites] Br J Haematol. 1992 May;81(1):52-7 [1520624.001]
  • [Cites] Lancet. 1995 Jan 21;345(8943):143-8 [7823668.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):364-72 [7873387.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):603-6 [9207407.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):945-51 [9326194.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):93-100 [9359508.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1249-55 [9697880.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • [Cites] Br J Haematol. 2009 May;145(3):376-88 [19236609.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • (PMID = 20010621.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G8223452(65788); United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2820452; NLM/ UKMS28094
  •  go-up   go-down






Advertisement